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It has been known for over a century that the CA1 subregion of the hippocampus is more 
vulnerable than the CA3 to ischemic damage. While many studies have been conducted, the 
exact mechanism is still unknown. Ectopeptidases are membrane-bound enzymes whose 
catalytic domains face the extracellular space. Traditionally, their role was believed to only 
involve clearance of active peptides but recent studies have shown that they play an important 
role in regulating peptide activity. Here we report the quantitative measurement of ectopeptidase 
activity using electroosmotic push-pull perfusion coupled to offline capillary liquid 
chromatography. This method revealed a three-fold higher aminopeptidase activity hydrolyzing 
the neuroprotective peptide Leu-enkephalin in the CA1 region of the rat hippocampus. Inhibition 
of the higher aminopeptidase activity in the CA1 selectively protects this region from ischemic 
damage due to oxygen-glucose deprivation. This is the first report of spatially-resolved 
quantitative measurements of enzyme activity in intact tissue using native substrates. The studies 
in this dissertation combine both computational and experimental approaches to tackle a 
longstanding question in neuroscience.  
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1.0  INTRODUCTION 
Portions of the following introduction are reprinted with permission from ACS Chemical 
Neuroscience 2017 DOI: 10.1021/acschemneuro.7b00326. Copyright (2017) American Chemical 
Society.  
 
Stroke is the leading cause of adult disability in the U.S, with a new stroke case occurring every 
40 seconds1. The hippocampus, the center of learning and memory in the brain, is one of the 
most severely affected regions in stroke. Like other brain structures, its proper functions rely on 
the transmission of chemical signals over both short and long distances. Extrasynaptic or volume 
transmission of neuropeptides is one important way by which neurons communicate. Unlike 
synaptic transmission, where chemical messengers travel only a short distance to bind to 
receptors within the synapse, molecules often leave the synaptic cleft or are directly released into 
the extracellular space (ECS) in volume transmission. Factors that govern this process include 
quantity of neuropeptides released into the ECS, reuptake (if any), diffusion, and degradation by 
enzymes. Thus, the ECS of the brain holds valuable chemical information. Having quantitative 
tools capable of extracting and understanding this information could be extremely fruitful in 
understanding the physiology and pathophysiology of the hippocampus and other regions of the 
brain.  
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1.1 THE HIPPOCAMPUS AND ISCHEMIA 
The hippocampus is the center of learning and memory. The Alexandrian school of medicine 
thought the curved structure resembled the horn of a ram and thus named the hippocampus 
Cornu ammonis2. This terminology survives to this day in the acronym of the different CA 
subfields of the hippocampus proper. The term “hippocampus” refers to the CA fields identified 
by neuroanatomist Rafel Lorente de Nó3 and should not be confused with the term “hippocampal 
formation.” The latter refers to the entire hippocampus plus the dentate gyrus (DG), subiculum, 
and entorhinal cortex2. As originally categorized by Lorente de Nó, there are three main CA 
subfields, the CA1, CA2, and CA33. The pyramidal cells in the CA2 and CA3 are greater in size 
that those in the CA1. The CA3 is also innervated by the mossy fiber pathway from the DG 
while the CA1 is not. The existence of the CA2 region has been questioned for many years, but it 
is generally accepted that it does exist as a narrow region between the CA1 and CA32. It is 
characterized by large pyramidal neurons like those in the CA3 but, like the CA1, is not 
innervated by the mossy fiber pathway. This dissertation will focus herein on the CA1 and CA3 
subfields only.  
 
Figure 1. Propidium iodide image of organotypic hippocampal slice culture exposed to 200 μM N-methyl-D-
aspartic acid (NMDA) for 40 min. The CA1 has higher cell death than CA3, indicated by more fluorescence. 
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It has been known for over a century that the hippocampus responds selectively to insults 
such as ischemia, with the CA1 region being much more susceptible to damage (Figure 1)4. This 
phenomenon was first observed in a patient in 1962,5 and demonstrated in transient ischemia 
models of rats and gerbils in the 1980s,6,7 and rat hippocampal slice models in 19908, showing a 
time course of “delayed neuronal death.” This delay is characterized by an initial onset of 
damage within the first 24 hours and results in maximum damage around 48-72 hours post-
ischemia9. This delay provides medical professionals with a window immediately after the 
ischemic event during which treatment can reduce or reverse the damage. There have been 
numerous molecular studies focused on excitotoxicity and abnormal calcium influx, oxidative 
stress and reactive oxygen species (including work done in our group10), as well as apoptotic 
processes and structural changes (reviewed in Dirnagl et al.11 and Schmidt-Kastner et al.12). 
Changes in protein expression have also been observed, including suppressed protein synthesis 
in the CA1 at 6-hours and 3-days post-ischemia13-15 as well as post-translational modifications16-
18. Despite extensive studies, the exact mechanism behind the selective vulnerability of the CA1 
region has not been decisively determined. There is, however, some consensus that this 
vulnerability involves calcium-related pathways4,12,19-21.  
1.2 ENKEPHALINS AND NEUROPROTECTION 
Since the discovery and characterization of endogenous opioids and their receptors in the 
1970s22-26, four major families have been identified: preproopiomelanocortin, preproenkephalin, 
preprodynorphin, and proorphanin27-33. The products that are cleaved from these precursors are 
the active peptides that bind to the various opiate receptors. One of these active products is called 
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enkephalin (cleaved from preproenkephalin). Over 90% of the opioid peptide activity isolated 
from the brain and gut were found to be from Leu-  (YGGFL) and Met-enkephalins (YGGFM)34. 
Interestingly, the sources of the endogenous enkephalins differ in the different subregions. In the 
CA1, fibers from interneurons provide a source of enkephalins35 while in the CA3, the mossy 
fibers from the DG provides an abundant amount35. It is known that enkephalins are stored in 
dense-core vesicles and are released extrasynaptially36-38. Thus, even though they can be released 
at the synaptic junction and act cooperatively with classical neurotransmitters, they may also 
diffuse to other targets over longer distances or be released outside of the synapse altogether 
(reviewed in Hokfelt39). Like other opioid peptides, the actions of enkephalins are produced via 
their binding to opioid receptors. β-endorphin has high affinity for μ- and δ-opioid receptors 
(DOR); dynorphins have the highest affinity for κ-opioid receptors; and enkephalins have the 
highest affinity for δ-opioid receptors40. DOR expression has been found in both pyramidal and 
non-pyramidal cell types in the hippocampus41,42 (reviewed in Gendron et al.43) and it has been 
suggested that DOR action is site-dependent and may be coupled to different second messengers 
at different locations41.  
Interestingly, numerous studies have shown that DOR activation is neuroprotective. For 
example, the upregulation of DORs during hypoxic preconditioning, in which the tissues are 
exposed to a sub-lethal level of hypoxia prior to the actual hypoxic event, can protect neuronal, 
cardiac, and retinal tissues from hypoxia44-46. Furthermore, as mentioned previously, DOR 
activation is thought to decrease hypoxia-induced Ca2+ levels by inhibition of L-VGCCs and 
activation of K+ channels47,48.  Zhang et al. demonstrated that DOR activation protects cortical 
neurons against glutamate-induced injury49, which mimicks the excitotoxicity that occurs during 
ischemia. Severe hypoxia has been shown to decrease endogenous Leu-enkephalin while 
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hypoxic preconditioning increased both DOR mRNA and protein levels as well as reversed the 
decrease in YGGFL caused by severe hypoxia44,50. Moreover, preconditioning the neurons with 
opioid peptides prior to ischemia results in reduced brain infarct volume and improved 
neurological functions 24-hours post-occlusion in male rats51. Elevated endogenous opioid 
peptides had a similar effect on reducing infarct volume46. In summary, opioid peptides such as 
Leu-enkephalin are neuroprotective to neurons against ischemic damage through activation of 




Enkephalins, like other neuropeptides, are different from classical neurotransmitters such as 
glutamate in several ways: 1) they are stored in dense-core vesicles, which are larger than 
synaptic vesicles and can participate in volume transmission36,38, 2) intense stimulation is often 
 
Figure 2. Schematic of aminopeptidase N (APN), an ectopeptidase whose catalytic domains face the 
extracellular space. APN cleaves YGGFL into its major product GGFL. 
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required to induce release of neuropeptides52, and 3) they are primarily limited by extracellular 
degradation and diffusion but not so much by reuptake53. One of the primary players in the 
degradation of neuropeptides in the ECS is a group of enzymes called ectopeptidases. 
Ectopeptidases are a family of membrane-bound proteins whose catalytic domains face the ECS 
(reviewed in Ou et al.54). Evidence suggest that only ~10-20 ectopeptidases are responsible for 
the inactivation of neuropeptides in the central nervous system55-61.  This was believed to be their 
only role until studies have shown that they also alter the activity of many peptides important to 
growth processes, cell survival, and stress response62-66, to name a few examples. The idea that 
ectoenzymes can be sites of peptide regulation was first proposed by Davis and Konkoy in 1995 
and is summarized in their review67. Since then, several prominent ectopeptidases such as 
dipeptidyl peptidase IV (DPPIV, EC 3.4.14.5), aminopeptidase N (APN, EC 3.4.11.2, Figure 2) 
and neutral endopeptidase (NEP, EC 3.4.24.11) have been targeted for therapeutic treatement of 
specific disease states68-71. Interestingly, it was recently revealed that the activity of 
ectopeptidase themselves can be altered due to trophic and/or pathological factors. For example, 
acute immobilization stress in rats caused changes in NEP and insulin-regulated aminopeptidase 
(IRAP, EC 3.4.11.3), two aminopetipdases that regulate anxiolytic peptides66. On the other hand, 
ischemic preconditioning has been shown to restore the activity of NEP and endothelin-
converting enzyme 1 (ECE-1, EC 3.4.24.71) that hydrolyze toxic αβ72. Furthermore, NEP 
activity has been shown to be altered in stroke73. Given this collective evidence, ectopeptidase 
activity is a largely unexplored but important modulator of peptide activity.   
 7 
1.4 MEASURING ENZYME ACTIVITY EX VIVO AND IN VIVO 
This section is part of a review submitted to the Annual Review of Analytical Chemistry74. 
  
Many different enzymes catalyze chemical transformations that alter or control peptide activity 
and concentration. Enzymes also are implicated in various physiological disorders, including but 
not limited to stroke, diabetes, Parkinson’s, Alzheimer’s, and cancer. Due to the immense need 
to identify, localize, and characterize the role of enzymes, several different tools have been 
developed to study them. While there are many approaches to studying enzyme activity, each 
approach has benefits and limitations. The following discusses the pros and cons of some of the 
recent methods in probing enzyme activity ex vivo and in vivo. This is by no means a 
comprehensive picture of all literature but an assessment of selected techniques that focuses on 
application related to this dissertation (e.g. stroke, ischemia, oxygen-gluocse deprivation, etc.) or 
measurement of enzyme rates.  
There are a couple of categories of fluorescence-based methods. One such method is 
zymography. The term is defined as “visualization of enzymatic activity by substrate 
conversion.”75 It was first used to measure enzyme activity in tadpole tissue76. ISZ was used to 
discover elevated MMP-9 activity in the infarct core of ischemic and hemorrhagic human 
tissues77. This increase was attributed to elevated MMP-9 expression near blood vessels due to 
neutrophil infiltration and activated microglia. Ziemka-Nalecz et al. discovered increases in 
oxygen-glucose deprivation (OGD)-induced MMP, which contributed to the progression of 
gliogenesis in organotypic hippocampal slice cultures (OHSCs)78. This microglial proliferation 
along with elevated MMP activity could play a role in massive loss of pyramidal neurons in the 
CA178. The advantage of ISZ is its ability to provide quantitative information about enzyme 
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activity in a spatially-dependent manner. The drawback is that it is used almost exclusively to 
study matrix metalloproteinase activity in slices. In the last decade, the development of protease-
activated fluorogenic probes led to the development of in vivo zymography (IVZ). Early work 
relied on nonspecific substrates for measuring general enzyme activity79 but more specifically 
targeting probes have been created since80. In a typical experiment, heavily fluoresceinated 
native collagens are injected in vivo, where they are degraded and unquenched, resulting in an 
increase in fluorescence intensity. IVZ has been used to study the degradation of type I and type 
II collagens in the zebrafish embryo during development81. It was found that more hydrolysis 
occurs later in development than earlier stages. A classical zymography substrate is DQ-
collagen, in which the “DQ” prefix indicate that it is an analog of the native peptide with 
excessive amount of fluorescent tags, which results in self-quenching. Keow et al.82 improved 
upon this method by replacing the DQ-collagen substrate with a Förster (or fluorescence) 
resonance energy transfer-quenched fluorophores. The main difference here is that the substrate 
now consists of a fluorophore and quencher moiety linked by a 10-amino-acid sequence. The 
benefit of this modification is that there is greater control over the linking sequence, allowing for 
better targeting of specific enzymes. Moreover, the variety of fluorophore/linker combinations 
and their different spectral properties allows for the measurement of multiple enzyme activities 
simultaneously82. Vandooren et al. provides a detailed review of zymography techniques through 
201375.    
Another type of fluorescence-based method is based on activity-based probes (reviewed 
in Razgulin et al.83). In a typical experiment, there is a quenched fluorescent probe that binds 
irreversibly to an enzyme target, upon which the attenuating linker is cleaved off and the probe 
fluoresces. The advantage of this method is high sensitivity and selectivity. The drawback is that 
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the substrate is covalently attached to the enzyme target, thereby preventing any dynamic 
monitoring. Furthermore, experts in the field also recognize that the one enzyme-one fluorescent 
molecule stoichiometry prevents amplification of the signal. Activity-based probes are primarily 
used for imaging tumors by monitoring enzymes like β-galactosidase84.  
 Matrix assisted laser desorption/ionization (MALDI) is a powerful technique due to its 
high sensitivity and spatial resolution. It does not require any tags, such as fluorophores, making 
it agreeable for tissue-based studies85. The Andersson group has combined mass spectrometric 
imaging with in situ histochemistry to discover differential hydrolysis of the neuropeptide 
dynorphin B in different regions of the rat brain85. The authors perfused both hemispheres of the 
rat brain with exogenous dynorphin B  and only one of the hemispheres with selective inhibitors 
in an effort to study the potency of these inhibitors on dynorphin B hydrolysis. This is relevant to 
Parkinson’s disease research, as there are elevated levels of dynorphin B in the striatum and 
substantia nigra in patients with Parkinson-related dyskinesia. The Sweedler group used 
MALDI-TOF/TOF with a D-amino acid containing peptide discovery funnel approach to detect 
the D-form of any common chiral amino acids86,87. Using this approach, they discovered two D-
amino-acid-containing peptides in Aplysia californica, one of which was GDYDFDD, a D-amino 
acid peptide that may play a role in feeding and locomotor circuits through the action of 
isomerases87.  
So far, most of the discussion has been focused on imaging-based methods. One of the 
main non-imaging methods for measuring enzyme activity is to utilize physical probes such as 
microdialysis88. In this technique, there is an inlet and outlet capillary inside a stainless steel 
cannula that ends in a porous membrane at the tip. The length of the membrane is approximately 
1-4 mm long and ~250 μm outer diameter (o.d.). The technique utilizes the dialysis principle in 
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that a membrane permeable to water and small molecules separates two fluid compartments, i.e. 
the extracellular space of the tissue and chamber inside the probe, which is constantly perfused 
with artificial cerebral spinal fluid (aCSF). There are two configurations of the inlet and outlet – 
either concentric or side-by-side. Due to the “closed-system” nature of the probe, microdialysis 
samples are free of brain tissue since exchange across the membrane is facilitated by diffusion89. 
The substrates can be introduced locally to the tissue from the inlet, across the membrane, and 
into the tissue ECS. Hydrolysis products can then diffuse back across the membrane and be 
collected and quantified. The main appeal of microdialysis is its breadth, particularly in its ability 
to couple to a variety of quantitation methods as well as the variety of analytes it can study. One 
of the main limitations of microdialysis is its size, which results in damage to the vasculature and 
resulting foreign body response, but there have been recent efforts in miniaturizing the probe size 
by microfabrication90. In vivo microdialysis measured elevated extracellular glutamate 
concentration in the periphery of the injured region after focal cerebral ischemia91. In another 
study, in vivo microdialysis detected increased adenosine concentration as a result of 
lysophosphatidylcholine (LPC) administration92,93. Since adenosine is generated from 
dephosphorylation of adenosine monophosphate by the membrane-bound enzyme ecto-5’-
nucleotidase, this observation was taken as an indirect evidence that there was elevated ecto-5’-
nucleotidase activity as a result of LPC administration. Retrodialysis with a protein kinase C 
antagonist abolished ecto-5’-nucleotidase activity due to LPC. This led the authors to conclude 
that LPC results in elevated ecto-5’-nucleotidase activity via protein kinase C pathway. 
Neuropeptide degradation has also been investigated using in vivo microdialysis. For example, 
dynorphin degradation/processing was found to be reduced in the dopamine-depleted hemisphere 
of the hemiparkinsonian rat model94. There have also been human microdialysis experiments. In 
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one study, kinetics of cortisol metabolism by 11β-hydroxysteroid dehydrogenase (11βHSD) was 
determined by infusing the subcutaneous adipose tissue of human patients with isotopically-
labeled substrates and subsequently measuring the amount of isotopically-labeled hydrolysis 
products. 11βHSD type 1 (11βHSD1) can catalyze the reduction of cortisone to cortisol in the 
presence of the cofactor nicotinamide adenine dinucleotide phosphate, or NADPH. It was shown 
using other methods that11βHSD knockout mice on a high-fat diet were rescued from obesity 
and hyperglycemia95-97. In one microdialysis study, the subcutaneous adipose tissue of human 
patients was infused with 1,2,6,7-[3H]-cortisone and 1,2[3H]-cortisone and 1,2[3H]-cortisol were 
measured in the dialysates98. 11βHSD1 activity was inferred from the steady-state concentrations 
of the two species using unlabeled cortisol and cortisone as internal standards. It was found that 
obese subjects had more rapid conversion of [3H]-cortisone to [3H]-cortisol, indicating higher 
11βHSD1 activity. The diffusional exchange rates of cortisone and cortisol across the 
microdialysis membrane were comparable and thus the differences in the cortisone and cortisol 
products were not due to mass transport across the membrane. 
One of the main benefits of microdialysis is that it has the ability to measure the fates of 
multiple substrates, products, and enzyme activities. Wang et al. implanted microdialysis probes 
into each side of the dorsal spine of freely moving rats and infused with MMP-1 and MMP-2/-9 
substrates via retrodialysis99. MMP-2/-9 share substrates and were thus indistinguishable in this 
case. Dialysates were collected every 30 min for 3.5 hours and subjected to LC/MS/MS analysis. 
The authors performed a blank dialysate experiment to see if any MMPs or other proteolytic 
enzymes were collected during the sampling. In this control experiment, MMP substrates were 
not introduced via retrodialysis but were instead spiked into the dialysate after collection. 
Through this approach, the authors found no significant enzyme activity in the dialysate until 7 
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days post-implantation. Next, retrodialysis was used to introduce MMP-1 and MMP-2/-9 
substrates into the tissue. It was found that the concentrations of MMP-1 and MMP-2/-9 N-
terminal products (NTPs) stabilized around 90 min at 2.6 μM and 3.1 μM, respectively. These 
were approximately 7-fold lower than what was reported in vitro. Retrodialysis of the broad-
spectrum MMP inhibitor GM 6001 reduced MMP-1 activity by 29% and MMP-2/-9 activity by 
22%. This was also lower than expected based on in vitro studies. To confirm the activity of 
MMPs near the tissue, the authors then explanted tissues from near the probe and far from the 
probe for zymography measurements of MMP activity. They found that there was actually higher 
MMP activity in the encapsulated tissue around the probe than in normal tissue, suggesting that 
long-term microdialysis implantation activated MMP-1, -2, and -9 and altered the tissue 
biochemistry99. Interestingly, this has been an active field of study in recent years, culminating in 
the discovery that the microdialysis probe implantation causes foreign body response100. In the 
short term, this foreign body response can influence measurements. In the long term, it can result 
in a scar tissue around the probe that reduces probe recovery of species in the ECS. This may 
explain the low MMP products seen in the example above99. Fortunately, recent strategies have 
been developed that show promise in minimizing the effects of the probe, including retrodialysis 
of the anti-inflammatory glucocorticoid dexamethasone101-105.  
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The other sampling-based technique has been developed by our lab using electroosmosis instead 
of pressure to drive fluid flow. Electroosmosis (Figure 3) is the bulk fluid movement that occurs 
when an electric current is passed through a fluid-filled conduit with charged walls, such as fused 
silica capillaries. Due to the accumulation of mobile counterions near the wall from electrostatic 
interactions, the application of an electric field induces movement of these mobile counterions 
that “carries” the rest of the electroneutral solution with it through diffusion of momentum54. A 
shear plane forms in the double layer at the wall that separates the mobile counterions and the 
fixed counterions on the wall surface. The electrostatic potential at this plane with respect to a 
point in the electroneutral solution is the zeta (ζ) potential. The magnitude of this potential, along 
with the magnitude of applied current, the dynamic viscosity of the solution, and the bulk 
conductivity of the electrolyte solution, determines the magnitude of the EO flow rate54. 
 
 
Figure 3. Zoomed in schematic of the double layer near the capillary wall. Upon application of an external 
current through an electrolyte-filled conduit, a stationary layer of counterions accumulate at the wall surface. 
Another layer of mobile counterions also accumulate just outside of this stationary layer. The potential at the 
imaginary plane between mobile counterions and stationary counterions with respect to the electroneutral 
solution is the zeta-potential. 
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Sampling using EO is possible because the ECS of the brain is essentially a network of conduits 
with charged walls with a measurable ζ-potential106, allowing for EO-driven flow to introduce 
and/or collect species. There are two generations of EO-based sampling techniques for 
measuring enzyme activity ex vivo in tissue cultures, as described below. All of the work done is 
on organotypic hippocampal slice cultures, which is described in more detail later in Chapter 3. 
More detailed, mathematical overview of the EO flow basics can be found in this review from 
our lab54. 
 
In the first generation of EO sampling, a typical experiment consists of positioning the 
proximal end of a fused silica (sampling) capillary on top of an OHSC with the distal end (the 
farther end with respect to the tissue) in an electrode-containing vessel. A second electrode is 
placed in the same bath as the OHSCs to complete the circuit. The electrodes are connected to a 
current source. Substrates are added to the bath underneath the insert membrane, on top of which 
OHSCs are grown. Upon the application of a current, fluid flows from the bath beneath the 
culture, through the tissue culture, and into the sampling capillary. Ectopeptidases hydrolyze the 
exogenous substrates being carried through by EO flow. EO sampling has been integrated with 
 
Figure 4. Schematic of EOPPP, the second-generation technique.  
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microfluidic capillary electrophoresis coupled to confocal laser-induced fluorescence 
detection107,108. The distal end of the sampling capillary is directly attached to the microfluidic 
device. Thiols collected from the extracellular space in the CA3 react with ThioGlo-1 dye in the 
reaction channel before separation by electrophoresis. This method was used to measure 
endogenous free cysteine (11.1 ± 1.2 μM), homocysteine (0.18 ± 0.01 μM), and cysteamine 
concentrations (10.6 ± 1.0 nM) in the ECS of the OHSCs108. Cysteamine (CSH) is the active 
terminal product of synthesis and degradation of coenzyme A (CoA), an important cofactor for 
4% of all enzymes108. Wu et al. perfused the CA3 region of OHSCs with CoA and monitored 
changes in CSH and pantetheine (PSH) concentrations (an intermediate in CoA catabolism) in 
the ECS using the integrated method described above107,109. Typical reaction time for these 
experiments was estimated by dividing the total effective volume of the tissue (taking into 
account the porosity of the medium) by the flow rate and was determined to be 55 s. Plotting 
CSH product as a function of initial CoA concentration yielded a Michaelis-Menten curve, from 
which the overall reaction rate of the CoA  CSH can be extracted. Because of the high flow 
rates used in the EO sampling method (hundreds of nL/min), the entire OHSC is filled with the 
substrate within seconds, and consequently the assumption that the initial substrate concentration 
does not change can be used. Thus the Michaelis-Menten equation can be applied to these 
measurements. Wu et al. reported an apparent Vmax(app)  = 7.1 ± 0.5 nM/s and Km(app) = 16 ± 4 μM 
for the overall enzymatic degradation of CoA in the CA3. The word “apparent” here refers to the 
overall kinetics for a multi-step enzyme reaction. Furthermore, fitting the Michaelis Menten 
equation to the plot of generated pantetheine as a function of CoA concentration revealed a 
comparable K’m for pantetheine (18 ± 6 μM) to that for CoA  CSH. This suggests that the final 
process in the CoA catabolism pathway, catalyzed by pantetheinase, is not the rate-limiting step 
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and is in the first-order regime. These reports provide the first rates of pantetheine and 
cysteamine formation in mammalian tissues, which had not been reported prior to this work due 
to lack of appropriate tools that can measure low endogenous concentrations. The authors also 
administered the disulfide forms of cysteamine and pantetheine, cystamine and pantethine 
respectively, two drugs that treat cystinosis, an autosomal recessive genetic disease that causes 
cysteine to accumulate in lysosomes. Cysteamine is the active molecule in the treatment of 
cystinosis. Wu et al.107 found that cysteamine is more rapidly produced from cystamine than 
pantethine, which agrees with the higher efficacy of cystamine in treating cystinosis. Since 
cysteamine is toxic in high doses, the rapid production of cysteamine from cystamine also agrees 
with findings that cystamine is more toxic than pantethine.  
EO sampling has also been coupled to offline capillary liquid chromatography (cLC) with 
electrochemical detection110. Rather than being coupled to a microfluidic device, the sampling 
capillary is removed from the OHSC after sampling is complete and the contents are ejected 
using a syringe containing 0.1% trifluoroacetic acid (TFA) to quench any enzyme reaction if 
enzymes were collected in the sampling process. The samples were analyzed with capillary 
liquid chromatography, reacted with biuret reagent postcolumn to make the peptides 
electrochemically active, and detected with amperometry at a carbon fiber microelectrode. Xu et 
al. used this method to measure the rate of hydrolysis in whole OHSCs. They found the major 
hydrolysis product to be GGFL. Inhibitor experiments indicate that the peptidase is likely to be 
bestatin-sensitive aminopeptidase, with Vmax = 770 ± 95 μM/s and Km = 1.2 ± 0.5 mM. Product 
generation was unaffected by GEMSA, captopril, and puromycin. This suggests that neither 
angiotensin-converting enzyme (EC 3.4.15.1) nor puromycin-sensitivity aminopeptidase (EC 
3.4.11.14) had any significant contribution the generation of the major hydrolysis product GGFL. 
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To improve spatial resolution, a second capillary was added such that it was pulled to a 
fine tip, inserted into the tissue, and filled with exogenous substrate for more controlled delivery 
of the substrate of interest to specific regions. This second-generation EO-based sampling 
technique is called electroosmotic push-pull perfusion (EOPPP, Figure 4)111. Rupert et al. 
coupled this technique with offline MALDI mass spectrometry to qualitatively determine the 
differences in galanin hydrolysis patterns in CA1 and CA3 of the OHSCs. Galanin is a 29mer 
peptide that reduces glutamate concentration after ischemia and is protective against glutamate-
induced damage112,113.  At both short and long reaction times, there was a significantly higher 
probability of finding short peptides with intact carboxy terminus (indicating aminopeptidase 
activity) in the CA3. At short but not long reaction times, there was a higher probability of 
finding long peptides with intact carboxy terminus in the CA3. No quantitative information was 
reported. The first-generation and qualitative work by EOPPP are reviewed in this paper from 
our lab54. 
The long-term goal is to determine quantitative differences in ectopeptidase activity in a 
spatial and temporal manner in order to elucidate the role of ectopeptidases in ischemic damage 
and neuroprotection. This dissertation investigates the EOPPP technique through dual lenses: the 
first is through computational model that assesses the technique in detail and provides a guide for 
data analysis, and the second is applying the technique to measure spatially resolved 
aminopeptidase activity in the context of hippocampal cell death as a result of oxygen-glucose 
deprivation.   
 
 18 
2.0  FINITE ELEMENT MODEL OF ELECTROOSMOTIC PUSH-PULL 
PERFUSION FOR MEASURING EX VIVO ENZYME ACTIVITY 
Reprinted with permission from Analytical Chemistry 2017 89(11): 5864-5873. Copyright 
(2017) American Chemical Society. 
 
Traditional measurements of enzyme kinetics in vitro involve adding the substrate to a medium 
containing whole cells or membrane fractions isolated via homogenization. Products in the 
supernatant can then be quantified using various analysis methods, including colorimetric assay, 
radiochemical assay, or HPLC analysis. In these experiments, the concentration of substrate, 
enzyme, and the reaction times are all under experimentalist control. However, for ex vivo or in 
vivo measurements of enzyme activity, the picture is more complex. Before any experimental 
measurements can be made, it is thus important to assess the concentration of substrate, product, 
and reaction times in the tissue during any given experiment. For first-generation of EO 
sampling, the high flow rates (hundreds of nL/min) fills the entire OHSCs with substrate(s) 
within seconds, and consequently the assumption that the initial substrate concentration does not 
change during an enzyme reaction can be made. The traditional Michaelis-Menten can be used in 
this case. For the second-generation EOPPP method, however, the flow rates are slower (10-50 
nL/min) and thus the tissue does not fill up with substrates within a matter of seconds as is the 
case for the EO sampling counterpart. Thus, the initial substrate concentration never reaches 
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steady-state in the tissue ECS and thus the traditional Michaelis-Menten equation cannot be used. 
Instead, the integrated Michaelis-Menten is required. In this form of the equation, there are three 
experimental parameters that can be measured (the initial substrate concentration and the amount 
of product generated at each substrate concentration) or calculated (residence time) and two 
unknowns (Vmax and Km). For EOPPP method, there is a gradient of substrate concentration and 
a distribution of velocities in the tissue ECS, both in a spatially-dependent manner. Simulations 
are thus needed to understand the method and guide data analyses in order to accurately measure 
Vmax and Km values in the tissue ECS.  
2.1 INTRODUCTION 
Techniques for measuring extracellular concentrations of solutes (such as neurotransmitters, 
metabolites, peptides, drugs) have been around for over half a century. Modern sampling tools, 
such as microdialysis88,89,114-119, low-flow push-pull perfusion120-124, and solid-phase 
microextraction125-127 are valuable assets for answering biological questions based at least in part 
on analytical measurements of solute concentrations in the extracellular space (ECS)54. These 
sampling procedures are a key component of the analytical methods that use them, and thus their 
influence on the analytical result must be well understood. For this reason, mathematical models 
of fluid and mass transport in these procedures have been developed and used to refine the 
application of sampling techniques. Various mathematical models have been developed for 
microdialysis (reviewed by Kehr)128. Bungay et al.118, following up on earlier and simpler 
models129,130, created a unifying approach by including both axial and radial diffusion to the 
probe. The numerical model provides outflow concentration given the inflow and external 
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medium concentrations as well as the probe membrane permeability and geometry. In recent 
years, Diczfalusy et al.131,132 developed a finite element method (FEM) model to predict the 
volume of tissue accessed by microdialysis. They introduced diffusion tensors from patient 
magnetic resonance imaging data into the FEM model for accurate computation of patient-
specific sampling volume around the microdialysis probe132. This accounts for anisotropy and 
heterogeneity in the brain, which are important to solute transport in the ECS as shown by 
Syková and Nicholson133,134. In contrast, there are fewer mathematical models of low-flow push-
pull perfusion and solid-phase microextraction. Cepeda et al.135 related sampling-induced cell 
death from low-flow push-pull perfusion to sampled fluid velocity, local pressure, and shear 
stress near the sampled site. Alam et al.136 developed a numerical model for solid-phase 
microextraction that simulates solute partitioning under various conditions of fluid agitation, 
fiber coating thickness, and the presence of a binding matrix. Taken together, these 
computational results provide insight into the complex processes that occur during sampling and 
a means to optimize experimental conditions without the need to perform a large number of 
experiments. 
There are in principle significant advantages to the use of electroosmotic flow to perfuse 
tissue as long as the tissue itself has a sufficiently large zeta potential, which is true for the 
brain137. The current path guides the direction of fluid flow and the current magnitude can in 
principle easily control the flow rate. Thus, we envisioned electroosmotic push-pull perfusion as 
a novel and useful approach, particularly to measure quantitatively (how fast) and qualitatively 
(what products) the rates of enzymatic hydrolysis of peptides by membrane-bound, extracellular 
peptidases. The first-generation electroosmotic sampling107-110,138 was used to determine 
extracellular cysteamine in organotypic hippocampal cultures and to characterize enzyme 
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activity in the tissue ECS related to neuropeptide degradation and coenzyme A catabolism. A 
second-generation111,139 electroosmotic push-pull perfusion (EOPPP) technique, which has better 
spatial resolution that its predecessor, was used to assess differences in product distribution from 
extracellular peptidase activity acting on the 29-amino acid neuropeptide, galanin, in the CA1 
and CA3 regions of organotypic hippocampal slice cultures.  
Our long-term goal is to determine quantitative and qualitative differences in enzyme 
activity over time and in a spatially dependent manner. For a method to be useful in this pursuit, 
or any investigations of the fate of molecules as they pass through the ECS, it must be able to 1) 
perfuse tissue and collect the perfusate for quantitative and/or qualitative analysis of the solutes 
introduced and reaction products produced, 2) control the average residence time of the active 
solutes, and 3) have the appropriate spatial resolution for the process of interest. EOPPP is in 
principle suitable to meet these needs. However, much like the case for microdialysis, low-flow 
push-pull perfusion, and solid-phase microextraction, there are parameters that are needed for 
quantitative interpretation of data but that cannot be measured easily (or at all) in EOPPP. A 
robust computational model would be very useful for understanding the fluid and mass transport 
events, for optimizing conditions, and for use in data interpretation to obtain quantitative results 
from the perfusion/collection of solutes and their reaction products.  
We previously developed a physical model composed of a slice culture and two probes. 
With this model, we investigated the potential drop in the tissue and correlated that with cell 
death in order to find “safe” conditions.31 We also used the model to show that the flow rate 
through the tissue culture under an applied current depended on the diameter of the sampling 
capillary111,139, but this was not discussed quantitatively.  The model described in this 
dissertation is built upon the previous model and also includes, solute transport and enzyme 
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kinetics. Thus, this model provides a more comprehensive, quantitative understanding of 
EOPPP, including the factors influencing solute distribution and residence time within the tissue.  
We show how to use the model to extract kinetic parameters of an enzyme in the tissue ECS 
based on EOPPP of the perfused substrate and collection of generated product. 
2.2 THEORY 
2.2.1 Finite element numerical model 
 
 
Figure 5. (Left) Side-view schematic showing the general setup of EOPPP, in which a source capillary is 
inserted into the tissue at a controllable depth and the sampling capillary rests on top of the tissue at some 
controllable depth. A buffer layer on top of the tissue maintains electrical contact between the sampling 
capillary and the tissue. Application of a current drives fluid and mass flow from source to the tissue to the 
sampling capillary. Not drawn to scale. (Right) The same geometry built in COMSOL Multiphysics showing 
the different experimental parameters.  Drawn to scale. The walls of the capillaries are not shown. 
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The model in COMSOL Multiphysics (v5.2) simulates electroosmotic flow (“Electric Currents” 
and “Free and Porous Media” modules) as well as solute transport and reaction kinetics 
(“Transport of Diluted Species in Porous Media” module). A 3-D geometry representing the 
capillary lumens and tissue culture was built on the COMSOL Multiphysics geometry interface 
using simple shapes and parametric curves (Figure 5). The buffer droplet between the sampling 
capillary and tissue surface was represented in the simulation as a truncated cone. The tissue was 
treated as a rigid, homogeneous porous material. The program applies a current boundary 
condition to create EO flow.  
EO flow in a porous medium140-142 can be modeled as a body force resulting in a 
modified Darcy’s law (Eqn. 1), 
         [1] 
where η is the dynamic viscosity (Pa s), κ is the permeability (m2), u is the superficial velocity 
(m/s), P∇ is the  pressure gradient (Pa/m), ρeff is the effective charge density of the fluid (C/m3), 
and φ∇   is the gradient of the electric potential (V/m). The superficial velocity is the volume 
flow rate divided by total cross-sectional surface area (including the impermeable portion of the 
medium). The interstitial velocity is the average velocity in the macroscopic direction of flow 
through the interstitial space of the porous medium. In order to determine the effective charge 
density, we started with an equation for superficial electroosmotic velocity in a porous 
medium111,143: 
          [2] 
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where εw is the permittivity of water (F/m), ζ is the zeta-potential (V), ε is the porosity, and λ is 
the tortuosity (or , where l is the length of the curved path and L is the length of the straight 
path through the porous medium). By equating the superficial velocities in Eqns. 1 and 2, in the 
absence of a pressure gradient, the effective charge density is 
          [3] 




η wPu          [4] 
In the capillaries and buffer layer between the sampling capillary and tissue, the Navier-Stokes 
equation is used.  
In order to save computational time, we shortened the length of the capillaries from 30 
cm to 2 mm. This truncation affects the pressure resulting from differences in ζ-potential 
between two adjacent media (capillary and tissue) through which the current flows. In order to 
account for this truncation, we defined boundary conditions at the inlet (to the source capillary) 
and outlet (from the sampling capillary) as “Hagen-Poiseuille” boundaries that define the 
pressure drop in the missing length for an incompressible Newtonian fluid with laminar flow:  
2
8 LmP uη∆ = ∆
a
          [5] 
where ΔP is the pressure drop in the missing length of capillary, Lm is the missing length of the 
capillary, Δu is the difference between wall velocity and average fluid velocity at the exit of the 
truncated capillary, and a is the radius of the capillary. The Hagen-Poiseuille boundary condition 
takes advantage of the fact that the flow profile is constant in this portion of the capillary to 
determine the pressure drop that would have been generated if the missing length had been 
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included in the geometry. All boundary conditions are defined on pages S-5 to S-7 of the 
Supporting Information. 
The module “Transport of Diluted Species in Porous Media” uses the following equation 
for each species, ‘i’: 
 
     [6] 




∂  (M/s) is the change 
in concentration with respect to time, Ri is a reaction rate (M/s)), u is the superficial velocity (m/s 
from Eqn. 4), De,i is the effective diffusion coefficient (m2/s), and μep,i is the effective 
electrophoretic mobility (m2/Vs). Here, the term “effective” refers to the incorporation of 
tortuosity to obtain a value of a parameter originally determined in free solution that would be 
observed macroscopically in the porous medium. The effective diffusion coefficient in a porous 
medium is 
 
144, where D is the diffusion coefficient in free solution. The terms on the right-
hand side of the equation represent, respectively, chemical reaction, convection, diffusion, and 
electrophoretic migration.  
Two approximations were made to simplify the calculations. First, we modeled the brain 
as a rigid porous medium. Work by Støverud et al.145 demonstrated no significant difference 
between using a rigid or an elastic model to simulate drug infusion (by pressure) into the brain 
for tissue permeability greater than 1.82 x 10-15 m2.  The permeability we used in the model is 10-
14 m2 146, thus the rigid model is appropriate for our system. Second, the 25 m layer of buffer 
that exists between the sampling capillary’s end close to the culture and the top surface of the 
culture is modeled as a fixed truncated cone shape (see Figure 5). In reality, this is an 
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approximation. The true surface shape depends on the surface tension of the droplet, the pressure 
outside the droplet, and the pressure within the droplet. The added complexity required to 
include this effect did not seem justified based on the fact that this droplet is merely a 
throughway for current and solute to pass from the tissue to the lumen of the sampling capillary. 
2.3 RESULTS AND DISCUSSION 
2.3.1 Model assessment 
The FEM model was built based on the assumption that the tissue is a homogeneous porous 
medium and uses several parameters from the literature, including viscosity (η = 8.9 x 10-4 Pa s), 
zeta potential of the capillaries (ζcap = -46.5 mV)54, zeta potential of the tissue (ζtissue = -22.8 
mV)147, peptide diffusion coefficients (DyaGfl = 4.45 x 10-10 m2/s)148, as well as tissue culture 
porosity (ε = 0.2-0.6)43,44 and tortuosity (λ = 1.2-1.6)149,150.  We wanted to know whether results 
from this model would be closely correlated to experimental observations. Thus, we assessed the 
 
 
Figure 6. Plot of moles of DYDAGDFDL (yaGfl) collected divided by initial yaGfl concentration in the source 
capillary [yaGfl]0 at the two different currents 5 and 15 μA. 
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transport portion of the model using data for the collection of a D-amino acid peptide 
DYDAGDFDL (yaGfl) with the EOPPP setup. Due to its D-amino acids, yaGfl is not rapidly 
hydrolyzed in the tissue and thus makes for a good sampling internal standard (this will be 
discussed in more detail later when we discuss using the FEM model for simulating enzyme 
activity). Both experimentally and computationally, the tissue ECS was perfused with exogenous 
yaGfl and the moles of yaGfl collected in ten minutes at two different currents (i = 5 and 15 μA) 
were obtained. Experimentally, this means measuring the moles of yaGfl collected via capillary 
liquid chromatography with UV-Vis detection. Computationally, this means performing a 
surface- and time-integral of the total flux of yaGfl at the entrance of the sampling capillary. 
Then the moles of yaGfl collected is divided by the initial concentration of yaGfl in the sampling 
capillary. This ratio, with units of nL, is related to the collection efficiency, which is defined as 
the fraction of the moles captured at the sampling capillary to those introduced at the source 
(Figure 6). As seen in Figure 6, this ratio at 5 μA was 14 ± 2 nL for experiments (mean ± SEM, n 
= 4) and 22 nL for the model. At 15 μA, the the ratio was 71 ± 7 nL for experiments (n = 11) and 
97 nL for the model. Given the complexity of the system, the fact that we are using estimates of 
tissue properties (e.g. porosity, tortuosity, permeability, etc.), and the general variability that 
comes with absolute moles collected because of tissue-to-tissue and rat-to-rat differences, the 
error between experiment and simulations is very reasonable. We also should mention that the 
currents used in many experiments for measuring enzyme activity are in the 10 – 20 μA range, so 
the 15 μA comparison has more weight. 
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2.3.2 Fluid transport 
 
There is a linear relationship between the current and electroosmotic flow rate in a homogenous 
medium111: 
          [7] 
where UEO is the electroosmotic flow rate, σ is the conductivity of the electrolyte itself, and i is 
the current. However, the ζ-potential of fused silica capillaries, -46 mV54, is different from that 
of the tissue, -23 mV147. For an incompressible fluid in a closed system, EO flow through a 
medium with non-uniform ζ-potentials results in non-uniform EO velocities. Mass balance 
requires that pressure be created to augment flow where the magnitude of the EO velocity is 
lower and to decrease flow where the EO velocity is greater. This generates a pressure gradient 
in the system54,151. The magnitude of this pressure difference increases linearly with the 
magnitude of the applied current and decreases nonlinearly with the inner diameter (i.d.) of the 
 
Figure 7. A) False color surface plot of pressure (normalized to applied current) in the source capillary, tissue 
and sampling capillary. The plane goes through the symmetry axis of the capillaries. B) Pressure/current vs. 
distance from the source tip (at the source center) along the indicated dashed line. While there is pressure 
drop in the capillaries, most of the pressure drop occurs between the two capillary tips in the tissue. The 
sampling capillary i.d. is 100 μm. 
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sampling capillary (discussed later) for a rigid porous medium of constant temperature 
containing a fluid with constant viscosity151. In EOPPP, we impose a positive current from the 
source to the sampling capillary so fluid flows from the source capillary with high EO velocity to 
the tissue with low EO velocity and then to the sampling capillary with a high EO velocity.  
Figure 7A shows a surface plot of the ratio of pressure to current during perfusion at steady state, 
with red indicating positive pressure and blue indicating negative pressure. Figure 7B shows a 
plot of that ratio as a function of distance from the source capillary, along the dashed line 
indicated in Figure 7A. The pressure/current ratio drop is around 2 Pa/μA at the tip of the source 
capillary and -0.3 Pa/μA at the sampling capillary. This pressure difference, though small, exists 
across a small distance, so it actually assists EO flow in pumping fluid through the tissue, as the 
flow rate is higher in the tissue than it would be without this effect.  
 
Our model shows that the contribution of this EO pumping phenomenon to the overall 
flow rate depends on the size of the sampling capillary151 as mentioned above and shown in 
Figure 8 (black symbols). The flow rate was calculated by integrating the superficial velocity in 
the sampling capillary over the cross-sectional surface area. In Figure 8, it is normalized to the 
applied current. The magnitude of the EO flow rate/current does not depend on capillary i.d. 
 
 
Figure 8. Plot of flow rate/current ratio as a function of sampling i.d. (black). Contribution from EO flow is in 
blue. Contribution from pressure (P) is in red. The total flow rates are shown in black (EO + P). Dashed line 
indicates the current-normalized EO flow rate predicted by. Eqn. 7. 
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(blue, Figure 8). In fact, the FEM calculations agree with Eqn. 7 quantitatively (see blue symbols 
and black dashed line). (This is further model validation.) To assess the contribution of the 
pressure generated by the ζ-potential mismatch to the total flow rate, we performed a separate 
calculation with the generated pressure (shown in Figure 7) as the only driving force in the 
absence of current. The pressure-induced flow rate/current ratio calculated for this pressure-only 
system is shown in red in Figure 8. We found that for a sampling i.d. of 100 μm, the pressure-
induced flow rate/current ratio is 0.87 nL/min/μA, accounting for nearly 60% of the total flow 
rate (1.63 nL/min/μA). On the other hand, for a larger, 250 μm, sampling i.d., the pressure-
induced flow rate/current ratio is 0.09 nL/min/μA, which is only about 10% of the total flow rate 
(0.86 nL/min/μA). The contribution of the pressure-induced flow for constant capillary length 
diminishes at larger sampling i.d.s because generated pressure for an incompressible Newtonian 
fluid is inversely proportional to the square of the capillary radius, as shown in Eqn. 5. The 
sampling capillary acts as an electroosmotic pump. 
There are several geometric parameters in EOPPP, including source tip i.d., source barrel 
i.d., how far the pulled tip is inserted into the tissue, sampling i.d., how far the sampling capillary 
is positioned above the tissue, and the length of the two capillaries (see Figure 18 in the 
Appendix A). Using our model, we found that the majority of the parameters do not significantly 
affect the flow rate in the ranges we examined (Figure 18), with the exception of sampling i.d. 
(which was discussed in the previous paragraph) and the lengths of the capillaries (see Figure 
18).  The sampling capillary i.d. has more influence on the flow rate than the source capillary i.d. 
because the source capillary barrel i.d. (200 μm) is larger than that of the sampling capillary. The 
lengths of the capillaries affect the pressure generated from the ζ-potential mismatch. The 
magnitude of the pressure generated is directly proportional to the length of the capillary, as 
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shown by the Lm term in Eqn. 5. This finding is consistent with the fact that in a homogeneous 
system where the ζ-potential is uniform, the only parameter that affects EO flow is the current, as 
described by Eqn. 7.  This is a favorable outcome. Of the suite of parameters listed above, 
current (controlling EO flow and contributing to EO pumping), sampling capillary i.d. , and 
capillary lengths (together controlling EO pumping) are the three easiest parameters to control. 
 
An interesting consequence of the EO pumping phenomenon is the ability to sample 
solutes that are otherwise impossible to obtain via EO alone. For neutral and cationic solutes, 
electrophoresis does not hinder sampling by EO. (In the case of cations, it actually facilitates 
sampling.) However, the ability to sample anions is dependent on the relative magnitudes of the 
bulk fluid velocity and electrophoretic velocity. Under typical experimental conditions (sampling 
i.d. = 100 μm, current = 10 μA), monovalent anionic solutes with MW equal to or greater than 
150 g/mol, such as glutamate and glutathione, can be sampled successfully (see Figure 9). Figure 
 
Figure 9. False color plots show the concentration gradients for increasing molecular weight (from left to 
right) and increasing sampling capillary i.d. (from bottom to top). Molecular weights are 50, 100, and 150 
g/mol going from left to right. Dimensions for the top three are as follows: source capillary 200 μm (barrel) 20 
μm (tip), sampling capillary 100 μm, length of capillaries were 30 cm each. Dimensions of the bottom three 
series are as follows: source capillary 100 μm (barrel), 10 μm (tip), sampling capillary 50 μm, and length of 
capillaries were 60 cm each. On the right, the concentration gradient for sampling of a neutral solutes (z = 0) 
is shown as a control. 
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19 shows that more highly charged anions (e.g. z = -2) could be collected if the MW is high 
enough. If the internally generated pressure is increased further by decreasing sampling i.d., 
increasing length, or a combination of the two, smaller solutes with the same charge can be 
sampled. In the example in Figure 9, we halved the sampling i.d. and doubled the length of the 
capillaries to 60 cm. As a result, a monovalent anion with a molecular weight of 100 g/mol could 
be sampled via EOPPP, according to computations (see Figure 9).   
2.3.3 Solute transport 
Most of the following discussion is based on the transport of yaGfl through the tissue via 
EOPPP. We will use the Péclet number in some of the following discussion to understand the 











bu            [8] 
where Pé is the dimensionless Péclet number, u is the interstitial velocity, and ‘b’ is the 
characteristic dimension of the system (in this case, ~100 µm). Pé can provide a semi-
quantitative assessment of the ratio of convective to diffusional solute velocity. When Pé is much 
less than one diffusion dominates while when Pé is much greater than one convection dominates.  
In the following, the stated concentrations of the solute in the tissue culture are all based on 
moles per volume of extracellular space. 
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Time-dependent calculations of the evolution of the solute distribution profile in tissue 
for the peptide yaGfl are summarized in Figure 20. The radially averaged solute concentration 
inside the sampling capillary reaches 95% of the steady-state level after 65, 42, and 32 s for i = 
10, 30, and 50 μA, respectively. Figure 10A shows a set of surface plots of concentration profile 
at t = 600 s for current = 0 (diffusion-only), 10 μA, 30 μA, and 50 μA EOPPP. Interestingly, the 
concentration profiles are asymmetrical: solute transport is clearly biased toward the sampling 
capillary, driven by the current flow between the two probes. This demonstrates an important 
advantage of EOPPP over diffusion-based as well as pressure-driven methods: there is a 
straightforward, instrumental means (i.e., current source) to establish flow rate with some control 
 
Figure 10. A) False color surface plot of the concentration profile at t = 600 s for i = 0 (diffusion only), 10, 30, 
and 50 μA. All concentrations are expressed as a percentage of initial concentration in the source capillary, c0. 
B) Distribution of solute in the tissue culture between regions with Pé greater than one (red) and less than one 
(blue).  C) 3D plot of concentration in several parallel XY planes at different Z positions. The concentration 
at the tissue surface is shown in more detail (from an eagle-eye perspective) on the right in order to illustrate 
the concentration gradient as well as the boundaries (white line) where Pé = 1 for the three different currents. 
The brownish-red ellipse/white ring left of center is the source capillary lumen. 
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over the directionality in the transport in tissue. This aspect is useful for introducing solutes to 
and sampling from specific regions, which is precisely what is needed to study activities of 
various processes, such as degradation, that affect the fate of solutes. The plots also reveal that 
an increase in current results in an increase in the perfused volume in the tissue. We estimated 
these volumes by determining the volume of the tissue where Pé is greater than one and 
convection dominates. These volumes are 7, 33, and 49 nL for 10, 30, and 50 μA, respectively. 
The shape of these volumes resemble hemispheres in Figure 10C, so the radii based on these 
volumes are 150, 250, and 286 µm, respectively. These provide a semi-quantitative estimate of 
the spatial resolution that can be achieved at different currents. Figure 10B is a bar graph 
showing what percentage of the total moles of solute in the tissue at steady-state is either in 
diffusion-dominant regions (Pé < 1) or convection-dominant regions (Pé > 1). An increase in 
current increases the proportion of solutes in the high Pé region, with only about 40% of the 
solute in convection-dominant regions at low current (10 μA) compared to more than 80% of the 
solute in the equivalent region at high current (50 μA). This suggests that an increase in current 
would result in an increase in solute transfer from the source capillary to the sampling capillary. 
One prominent feature of both Figure 10A and Figure 10C is the gradient of concentration that 
exists in the tissue. The highest concentration in the tissue is adjacent to the source capillary tip, 
with tissue concentrations that are nearly 100% of the initial concentration in the source capillary 
(c0). This concentration decreases to approximately 10-20% of c0 in the tissue directly under the 
sampling lumen and roughly 1% near the bottom of the tissue culture. In fact, from the eagle-eye 
view of the concentration distribution at the surface of the culture (far right in Figure 10C), it is 
clear that by the time the solutes reach the tissue surface to be collected into the sampling 
capillary, there is a gradient of concentration within the convection-dominant zones, the 
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boundaries of which are outlined by the white line. An increase in current increases the area of 
the tissue surface that is perfused with solutes. An increase in current, however, also increases 
the area of the tissue where convection dominates. This means that the average concentrations 
within the regions where Pé is greater than one decreases with increasing current. This is 
initially counterintuitive but it makes sense given the concentration profiles and the relative sizes 
of the convection-dominant zones seen in Figure 10C. Figure 21 in the Appendix A illustrates 
this further. It shows plots of the average concentration and the average Pé in the area where Pé 
is greater than one in planes perpendicular to those shown in Figure 10C. The concentration is 
low far from the source tip. It is a maximum at the source capillary tip, and then decreases to 
nearly zero within 100 μm below the tip and within 200 μm laterally. The Pé profile is similar to 
the concentration profile in both directions, with the highest value of Pé at the source capillary 
tip.  In the context of enzyme activity, this means that the concentrations of the substrates and the 
enzyme-substrate reaction time vary spatially. We will explore how this affects data 
interpretation relating to in vivo enzyme kinetics measurements in a later section. 
We define the collection efficiency of EOPPP as the moles of solute, yaGfl, collected 
divided by moles of solute injected. We hypothesize that the factors that significantly affect 
collection efficiency are those that control convection, diffusion, or both. We discussed 
previously how the sampling capillary i.d. influences the flow rate by affecting the magnitude of 
the internal pressure gradient generated due to the ζ-potential mismatch. Figure 22 shows that an 
increase in sampling i.d. decreases the collection efficiency. Doubling the sampling i.d. from 100 
to 200 μm, for example, reduces the collection efficiency from 44 to 40%. This small change is a 
result of two competing factors. The larger i.d. column creates a smaller pressure gradient, which 
reduces collection efficiency, but the collection area is larger which increases collection 
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efficiency. We also discussed previously that applied current is the other major factor that 
controls flow rate. Figure 22 demonstrates that increasing the applied current from 5 to 55 μA 
increases the collection efficiency from 33 to 73%. This is consistent with the observation made 
above that an increase in current results in a higher proportion of solutes in convection-dominant 
zones.  
 
In addition to the effects of changing experimental parameters on collection efficiency 
(e.g. sampling i.d. and current), there is an effect of the local tissue environment on collection 
embodied in ε and λ. Because ε and λ are interdependent, we examined these two properties of 
the porous medium collectively as a single dimensionless ratio, , called the formation factor 
(fF). This is a geological term that relates electrical resistivity in free solution to that in a porous 
medium152. Our calculations show that changes in fF had little effect on EO flow rate itself (see 
Figure 24). However, as seen in Figure 11, there is a significant effect of fF on solute transport. 
Increasing the fF decreased collection efficiency at all applied currents. To understand why, we 
need to look at residence time.  
 
 
Figure 11. Plot of collection efficiency as a function of formation factors under three different currents (10, 
30, and 50 µA). Collection efficiency was calculated as moles of yaGfl collected divided by moles of yaGfl 
injected. Shaded region indicate the range of values for fF for healthy organotypic hippocampal slice cultures. 
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Residence time is the length of time any individual solute spends in the tissue. It is an 
important parameter especially for enzyme kinetics because it determines how long the solutes, 
e.g. peptide substrates, are exposed to the different processes, e.g. degradation, in the ECS. The 
trajectories of the individual solute molecules in EOPPP will vary at least due to convection, 
diffusion, and the tissue environment. The consequence is that in any experiment there will be a 
distribution of residence times. We applied a Gaussian solute concentration pulse of 0.05 s 
standard deviation at the source capillary and observed the solute leaving the tissue over time at 
the interface between the tissue and the buffer layer. From this time distribution, we determined 
the first moment, tR, which is the mean time that the solute molecules spend in the tissue. Values 
of tR for fF 0.1, 0.2, and 0.3 are 4.2, 4.8, and 5.3 s, respectively, for applied current of 10 μA (see 
Figure 23). Thus, an increase in fF results in an increase in the average residence time in the 
tissue. In order to understand why, we need to revisit Péclet. 
 
 
Figure 12. Left) Series of false color surface plots showing the effect of fF on Pé. (Right) Line plot of Pé as a 
function of distance from source tip along the white dashed line shown in left panel (fF = 0.1). Distances 0-100 
μm are the tissue region, whereas 100-150 μm is the buffer layer between the sampling capillary and tissue. i 
= 10 μA for all plots here. Analogous plots for i = 30 and 50 μA are shown in Figure 25 in the Appendix A. 
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Figure 12 demonstrates how the fF affects Pé. On the left, the zones where convection 
and diffusion dominate are presented graphically in a false color cross sectional surface plot. 
Brown indicates zones where convection dominates, while the other colors indicate zones where 
diffusion dominates. On the right, the same information is presented in a more quantitative 
manner in the form of a line plot. Pé is between 400 (fF = 0.3) and 1400 (fF = 0.1) at the source 
probe tip and decreases to 5 (fF = 0.3) to 12 (fF = 0.1) at the tissue surface under the sampling 
capillary. These data suggest that if the tissue is less porous and more tortuous, 1) the volume of 
the tissue where convection dominates increases in size, and 2) there is a greater ratio of 
convectional to diffusional solute transport in the tissue. For example, the average interstitial 
velocities in the volume of tissue where Pé is greater than one are 6.7, 5.9, 5.6 µm/s for fF= 0.1, 
0.2, and 0.3, respectively (i = 10 µA). A decrease in fF results in higher current density in the 
ECS, thereby causing an increase in the interstitial velocity by EO. In contrast, the effective 
diffusion coefficient in a porous medium is related to the free diffusion coefficient by 144, 
thus a decrease in fF results in a decrease in effective diffusion coefficient in the tissue. While 
interstitial velocity is increased by a decrease in fF, diffusional transport is reduced, resulting in 
higher collection efficiency in low-porosity/high-tortuosity environments. We note that pressure-
driven velocities are heavily dependent on the permeability of the tissue, in contrast to EO-driven 
velocities, which are only minimally affected. (Rearranging Eqn. 4 and taking the pressure 
gradient to be zero shows that the superficial electroosmotic velocity is independent of 
permeability in a homogeneous medium at constant pressure.) This is explored in a simple model 
calculation in Figures S-15 and S-16. These figures show that EO flow delivers more fluid and 
solute to regions with lower fF than those with higher fF. In fact, the greater the difference in 
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porosity and tortuosity between two adjacent regions, the more effective EO flow is at 
transporting than its pressure counterpart. 
2.3.4 Quantitative estimation of enzyme Vmax and Km 
We have discussed thus far the fluid dynamics and mass transport of solutes in the tissue during 
EOPPP, the spatial resolution that can be achieved under various experimental conditions, the 
ability to control experimental parameters to tune the perfusion rate and reaction time, as well as 
the effect of local tissue environment on collection. These discussions have provided a broad 
understanding of the perfusion process and its general applicability to studying reactions in the 
ECS. This last section addresses how to obtain quantitative information about enzyme activity in 
the tissue from the perfusion data. An example reaction that can occur in the tissue is as follows: 
 
where YGGFL is Leu-enkephalin, a common endogenous opioid peptide in the brain ECS, and 
GGFL is the major hydrolysis product after cleavage by membrane-bound aminopeptidase(s) 
whose catalytic domains face the ECS54,110,111. The following discussion assumes a Michaelis-
Menten model but other appropriate models could also be used. 
In conventional laboratory in vitro measurement of enzyme kinetics, observed rates are 
so-called “initial rates” because the experimental observation is the reaction rate, and the initial 
substrate concentration changes very little during the monitoring of the reaction. The Michaelis-
Menten, or an analogous rate equation, is directly fitted to the data to derive parameters related to 
the reaction. In tissue measurements, this is not the case. When using natural substrates, 
observing the rate in real-time is difficult so a measurement of substrate or product concentration 
 40 
is often taken after a specific reaction time has passed. In addition, the substrate concentration 
may change significantly as it passes through the tissue. Thus, the integrated form of the 
Michaelis-Menten equation must be used instead. Furthermore, there is a range of substrate 
concentrations in the tissue due both to reaction and diffusion (see Figure 10). Thus, the 
parameters derived from fitting the integrated Michaelis-Menten equation to the measured 
quantities may need to take into account the difference between the laboratory initial substrate 
concentration and the actual initial substrate concentration in the tissue. 
Classical Michaelis-Menten kinetics describes the rate of product formation as a function 
of Vmax, the limiting rate at saturating substrate concentrations, Km, the substrate concentration 
when the observed rate is half of Vmax, and the initial substrate concentration exposed to the 
enzyme, S0. Beal first derived a closed form solution for product (or substrate) concentration as a 
function of S0 and time153 (and analytical approximations have been described by Goličnik154): 
        [9] 
where P is the concentration of product generated after time ‘t’ and W is the Lambert W 
function155,156 that can be found in several commercial software packages (e.g., Matlab, 
MathCad, Mathematica). An implicit solution for product or substrate can be derived as 
well157,158 which can be solved with a nonlinear solver.  In order to extract the appropriate kinetic 
parameters, P/S0, S0, and t must be known. The residence time, t, was discussed above. We 
consider P/S0, and S0 below. 
P/S0. During a sampling experiment, we can experimentally vary S*0 by changing the 
concentration of S in the fill solution in the source capillary. Herein, we use an asterick to 
differentiate between the initial concentration in the fill solution and that in the tissue ECS, S0. 
After perfusion is complete, we measure the concentration of product P, substrate S, and internal 
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standard IS collected in the sampling capillary by coupling EOPPP with capillary liquid 
chromatography (with absorbance, fluorescence, or mass spectrometric detection). The internal 
standard, yaGfl, has properties similar to the substrate. As we make the IS0 the same as S0, 
experimentally measured substrate and product concentrations are normalized to the measured IS 
concentration to give estimates of S/S0 and P/S0 respectively. This minimizes the effect of 
differences in fF on collection efficiency as well as analytical errors on the measured quantities 
(see Appendix A).  
We simulated a simple one-enzyme, one-substrate, one-product system that obeys the 
Michaelis-Menten model, for which the rate of product generation in the tissue domain is equal 
to . The geometry is the same as that described earlier for the EOPPP system. We 
simulated measurements at thirteen different values of S*0 ranging from 1 μM to 10 mM and 
nine different pairs of Vmax and Km values (all combinations of Vmax = 1, 10, 50 μM/s; Km = 100, 
200, 500 μM). It is important to note that the initial substrate concentrations used in this 
simulation span an extremely wide range encompassing pure zero order (the limit of Michaelis 
Menten at high substrate concentration), pure first order (low substrate concentration) and 
fractional order. Only in this way can both kinetic parameters, Vmax and Km, be determined.  
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The simulation provided the P/IS ratios, a surrogate for P/S0, in the sampling capillary, 
for each S0 after 600 s of perfusion as we do experimentally.  The simplest approach to obtain 
Michaelis Menten parameters is to fit Eqn. 9 to P/S0, S*0, and the first moment of the reaction 
time distribution tR to obtain values of V’max and K’m. The question is whether or not we can 
obtain estimates of Vmax and Km (the true values) from these primed values. The in silico 
experiments demonstrates that indeed we can. V’max and K’m values derived from the fitting were 
plotted against actual Vmax and Km values defined in the simulation. The fitting was done using 
both the entire time distribution and the first moment to compare and contrast the validity of 
using tR.  These results are summarized in the Figure 13 and in the Appendix A in Figure 29. 
Vmax and  V’max are directly proportional to each other when using either the full residence time 
distribution (slope = 10.6 ± 0.3, ± SE) or the first moment (slope = 11.3 ± 0.4) and the 
proportionality is independent of Km (Figure 13A). Km and K’m are directly proportional as well 
using either the full time distribution (slope = 2.8 ± 0.2, Figure 13B) or the first moment (slope = 
 
Figure 13. Correlation plot of inferred values of V’max and K’m vs. actual values of Vmax and Km in the tissue 
ECS. A) There was no statistically significant difference in using the time distribution or the first moment to 
estimate V’max and the values of V’max were not Km dependent. The values of V’max and Vmax are directly 
proportional. B) Correlation plot of K’m vs. Km when the time distribution is used. For Vmax ≤ 10 μM/s, K’m 
and Km are directly proportional. For high Vmax (>10 μM/s), the nonzero intercept is statistically different 
from zero. 
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3.0 ± 0.6), but only for low values of Vmax (≤10 μM/s). When Vmax is high (i.e. >10 μM/s), the 
full regression equation for K’m vs Km with a nonzero intercept should be used, taking into 
account that the magnitude of the intercept is Vmax-dependent (see Figure 29 in the Appendix A). 
Finally, the kinetic parameters estimated from fitting either P/S0 or S/S0 are not significantly 
different from each other for this single enzyme system that converts S to P (see Figure 29). 
Altogether, this provides a simple but reliable approach for data treatment and interpretation 
without the need for precise knowledge of S0 in the ECS.   
2.4 CONCLUSION 
Using FEM calculations, we have demonstrated the suitability of EOPPP as a method for 
measuring enzyme activity that can equally well be applied to other processes that affect the fate 
of solutes in the ECS. EOPPP can be used to introduce exogenous solutes via the source 
capillary and collect both exogenous and endogenous solutes (as well as any reaction products) 
via the sampling capillary. There are three instrumental parameters, namely current, sampling 
i.d., and capillary lengths that control the perfusion rate, the Péclet number, and, consequently, 
the residence time of the solutes in the ECS. Thus, the experimenter has control over the reaction 
time between the solutes and the enzymes in tissue. The current also influences the spatial 
resolution of the measurement.  
In addition to the three instrumental parameters, we found that the tissue’s local geometry 
(formation factor) also significantly affects Pé and collection efficiency. Our simulations 
demonstrate that by using an internal standard that has similar diffusion coefficient as the solute 
of interest and that cannot be degraded by enzymes minimizes the effect of tissue properties on 
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collection efficiency. All quantitative measurements of the amount of solute collected should 
thus be reported as a ratio to the amount of internal standard collected. Moreover, by making the 
initial substrate and internal standard concentrations equal, the amount of internal standard 
collected can be used as a surrogate for the amount of substrate collected if no enzymes had been 
present.  
There is a spatial distribution of solute concentrations and velocities. Both quantities 
follow a similar profile, with maximum levels near the source capillary tip that decreases steadily 
toward the tissue surface near the sampling capillary. In the context of enzyme kinetics, this 
means that kinetic parameters derived from the data must account for these variations. In silico 
experiments using the Michaelis-Menten model demonstrate that useful information about Vmax 
and Km can be obtained despite the complex profiles of S0 and Pé in the ECS. In applying 
EOPPP to biological questions, there are generally “experiments” and “controls.” The ratios of 
kinetic parameters (experiment to control) will be much less affected by the distribution of solute 
concentration and velocity in the ECS.   
We conclude that EOPPP is generally applicable to studying enzyme activity in the ECS. 
The spatial resolution is on the order of 100 - 200 m. Conditions can be altered to improve 
collection of  low-molecular weight anions. The model grants a simple approach to data 
treatment and interpretation to obtain useful information about actual kinetics in the tissue.  
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2.5 SUPPORTING INFORMATION FOR NUMERICAL MODELING 
2.5.1 Boundary condition for comsol multiphysics 
 
 
Figure 14. 3D geometry of EOPPP. A – sampling capillary; B – source capillary; C – 




Table 1. Boundary conditions for Electric Currents module in COMSOL Multiphysics v5.2 for EOPPP 
model. J is the current density, σ is the conductivity, V is the voltage drop, Je is the external current density 
source, n is the normal vector, and I0 is the applied current. 
Boundary/Domain Boundary condition Equation, if applicable 
All domains Current conservation 0)( =−∇⋅−∇=⋅∇ eJVJ

σ  
2-12, 14-21 Electric insulation 0=⋅ Jn

  
1 Terminal, current i = i0, where  
i0 = 10, 30, 50 μA 
13 Ground V = 0 
 
Table 2. Boundary conditions for Free and Porous Media Flow for EOPPP model. u is the superficial velocity, 
µeo is the electroosmotic mobility, E is the electric field, P is the pressure, Lm is the length of the capillary 
unaccounted for in the model geometry (the capillaries were truncated to save on computation time), η is the 
dynamic viscosity, Δu is the difference between the wall velocity and average velocity, a is the radius of the 
capillary, and f0 is the normal stress. 
Boundary Boundary condition Equation, if applicable 
6-7, 9-11, 15 Slip walls  
 
Figure 15. Mesh elements for EOPPP model. 
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8 Open boundary f0 = 0 
 
Table 3. Boundary conditions for Transport of Diluted Species in Porous Media module for EOPPP model. N 
is the flux, c is the concentration at any time t, c0 is the initial concentration, and D is the diffusion coefficient. 
*Boundary condition for residence time distribution (replaces concentration boundary condition). 
**Boundary conditions for calculating reactions. 
Boundary/Domain Boundary condition Equation, if applicable 
2-7, 9-12, 14-21 No flux 0=⋅− Nn

  
1 Flux 1 )( cDucnN ∇−⋅= 

 
13 Flux 2 )( cDucnN ∇−⋅= 

 
1 Concentration c = c0; c0 = 0.2, 2.2 mM  
1* Pulsed concentration c = gp1(t[1/s])*c0; sd = 0.05 s 













A, C, D Initial values c0 = 0 




Table 4. General fluid and porous properties for EOPPP. 
Domain(s) Property Value 
All Density (ρ) 1 x 103 kg/m3 
Permittivity of water (εw) 7.1 x 10-10 F/m 
Permittivity of vacuum (ε0) 8.85 x 10-12 F/m 
Dynamic viscosity (η) 8.9 x 10-4 Pa s 
A, B, C Conductivity (σ) of buffer111 1.43 S/m 
Capillary ζ-potential54 -46.5 mV 
D Porosity (ε)149,150  0.2, 0.4, 0.6 
Tortuosity (λ)149,150  1.2, 1.4, 1.6 
Tissue ζ-potential 106 -22.8 mV 
Electroosmotic mobility* 
(μeo) 
3.99 x 10-8 m2/( V s) 
Effective charge density* 
(ρeff) 
3.25 x 102 C/m3 
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Permeability (κ) 145 10-14 m2 
Conductivity of tissue* 
  
 




Diffusion coefficient, DYDAGDFDL 148 3.61 x 10-10 m2/s (free solution) 
7.37 x 10-11 m2/s (tissue) 
Diffusion coefficient, YGGFL148 3.36 x 10-10 m2/s (free solution) 
6.86 x 10-11 m2/s (tissue) 
Diffusion coefficient, GGFL148 4.45 x 10-10 m2/s (free solution)  
Diffusion coefficient in tissue D* = D/λ2 
IS0 (for no reaction) 200 µM 
S0 = IS0 (for reactions) 1-10,000 μM 
Vmax 1, 10, 50 μM/s  
Km 100, 200, 500 μM 
 
Figure 16. Two ways of visualizing the electroosmotic push-pull perfusion process in organotypic 
hippocampal slice cultures via finite element method calculations in COMSOL (top panel) and 
experimentally through TR3 fluorescence monitored by inverted IX-71 microscope (bottom panel). Dashed 
lines trace out the shapes and location of the source capillary and the lumen of the sampling capillary. Arrow 
indicates the tip of the source capillary. Time stamp is in minutes:seconds. The shift to a lighter blue hue 




Table 6. Boundary conditions for Electric Currents module in COMSOL Multiphysics v5.2 for 2D 
axisymmetric model. 
Boundary/Domain Boundary condition Equation, if applicable 
1, 6-9 Axial symmetry  
All domains Current conservation 0)( =−∇⋅−∇=⋅∇ eJVJ

σ  
2-12, 14-21 Electric insulation 0=⋅ Jn

  
10 Ground V=0  
11 Terminal, potential V = V0; V0 = 1000 V 
 
Table 7. Boundary conditions for Free and Porous Media Flow for simulating EOF in 2D axisymmetric 
model. 
Boundary/Domain Boundary condition Equation, if applicable 
1, 6-9 Axial symmetry  
3, 4, 12, 13 Slip walls  

















10 Inlet  
11 Outlet  
 
Figure 17. Mesh for 2D axisymmetric model. Letters denote the domains. A and B are tissue. C and D 
are capillaries. Numbers denote the boundaries. Boundaries 10 and 11 are pointing to the inflow and 
outflow boundaries (not shown), respectively. Tissue region B is actually a circular region with a 5-mm 
radius that spans outside the scale of this figure. The outermost boundaries of this region are open 




boundaries of domain 
B (not shown in 
Figure 17) 
Open boundary f0 = 0 
 
Table 8. Boundary conditions for Free and Porous Media Flow for simulating PDF in 2D axisymmetric 
model. 
Boundary/Domain Boundary condition Equation, if applicable 
1, 6-9 Axial symmetry  
2, 3, 5, 12 No slip walls  
10 Inlet P = 750 Pa 
11 Outlet P = -750 Pa 
Outermost 
boundaries of domain 
B (not shown in 
Figure 17) 
Open boundary f0 = 0 
 
Table 9. General fluid and porous matrix properties for 2D axisymmetric model. 
Domain(s) Property Value 
All Density (ρ) 1 x 103 kg/m3 
Permittivity of water (εw) 7.1 x 10-10 F/m 
Permittivity of vacuum (ε0) 8.85 x 10-12 F/m 
Dynamic viscosity (μ) 8.9 x 10-4 Pa s 
C, D Electroosmotic mobility 3.71 x 10-8 m2/(V s) 
Conductivity (σ) of buffer 111 1.43 S/m 
Capillary ζ-potential 54 -46.5 mV 
A Porosity (ε1) 0.2 
Tortuosity (λ1) 1.6 
Tissue ζ-potential 106 -22.8 mV 
Effective charge density* (ρeff) 186.49 C/m3 
Permeability* (κ) 6.78 x 10-15 m2 
Conductivity of tissue* 0.29 S/m 
B Porosity (ε2) 0.4 
Tortuosity (λ2) 1.4 
Tissue ζ-potential 106 -22.8 mV 
Effective charge density* (ρeff) 26.23 C/m3 
Permeability* (κ) 1.26 x 10-13 m2 
Conductivity of tissue* 0.29 S/m 
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2.5.2 Experimental section for model assessment 
Solutions and Reagents. Hank’s balanced salt solution (HBSS, Gibco by Life Technologies) was used as the running buffer during all sampling experiments. Model peptide DYDAGDFDL, yaGfl, was dissolved in HBSS for a final concentration of 200 μM. Solid Texas Red dextran conjugate 3kDa (TR3, Sigma Aldrich) was dissolved in HBSS for a stock concentration of 20 mM. This can be further diluted to a final concentration of 3-4 mM. All solutions were frozen until use. The injection standard GGFM was dissolved in 0.1% trifluoroacetic acid 
(TFA, Sigma Aldrich) HBSS solution for a final concentration of 16 μM. 
Organotypic hippocampal slice culture. Dissection and culturing techniques were adapted from Gogolla et al.159 and approved by Institutional Animal Care and Use Committee (IACUC protocol #14021579) at the University of Pittsburgh. Briefly, the freshly decapitated heads of postnatal 7-day-old Sprague Dawley pups were disinfected by submersion in 70% ethanol prior to dissection. The hippocampi were removed and 
chopped along the septotemporal axis at a thickness of 350 μm (McIlwain, model TC752). Slices were immediately transferred to a Petri dish and incubated at 4 oC for 30 min prior to plating. The slices were separated under a dissection microscope using microspatulas. Slices with intact laminar structures were chosen for plating. To plate, 2-4 slices were 
placed onto a single porous (0.4 μm) modified PTFE insert membranes (Millipore) and cultured in a six-well plate (Sarstedt) with 95% air/5% CO2 maintained at 36.5 oC. Culture medium is 50% opti-MEM (Gibco), 25% horse serum (Gibco), 25% HBSS with phenol red (Life Technologies, 14025076), and 1% D-(+)-glucose (Sigma Aldrich). The medium was 
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changed every 2-3 days (every other day for 4 cultures/well). The cultures can be kept alive ex vivo for up to 4 weeks. 
Sampling process and capillary liquid chromatography. EOPPP experiments were done as described previously111.  Fused-silica sampling (100 μm i.d., 350 μm o.d., Polymicro 
Technologies) and source (200 μm i.d., 350 μm o.d., Polymicro Technologies) capillaries were prepared by cutting each to 30 cm long using a Shortix capillary cutter with diamond blade (Scientific Instrument Services). They were then mounted onto capillary holders, filled with HBSS, and positioned using an electronic micromanipulator (model MP-285, Sutter Instruments, Inc.). One end of the sampling capillary was placed at a distance of 25 
μm above the organotypic hippocampal slice culture (see slice preparation above) that are grown on insert membranes, which floats on top of a 1.2 mL HBSS solution. One end of the 
source capillary was pulled to a tip of 20 μm i.d. (~35 μm o.d.), backfilled with yaGfl and 
TR3 solution, and inserted to a depth of 60 μm below the top surface of the tissue at a 45o angle. The other ends of the two capillaries were placed in two separate Petri dish filled with the same volume of HBSS. Pt electrodes in these latter dishes are connected to a high-voltage current source (model PS350, Stanford Research Systems). The application of a 
current (5, 15 μA) results in bulk flow from the source capillary, through the tissue, and into the sampling capillary. The TR3 was used to visualize the flow path with fluorescence microscopy. After 10 min of sampling, the current source was turned off and the contents 
of the capillary were pushed into a 10 μL solution of 16 μM GGFM in 0.1 % TFA in HBSS. The GGFM concentration measured by capillary liquid chromatography is used to determine the volume collected from the capillary. The sample was then analyzed using capillary reversed phase liquid chromatography (RSLC Nano, absorbance detection, 
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Thermo Fisher). Columns were packed locally (100 μm inner diameter x 1.7 μm particles, CSH-C18, Waters Corp.).  Moles of the yaGfl collected divided by the initial concentration of yaGfl in the source capillary is summarized in Figure 6 of the main text. 
2.5.3 Effect of different parameters on flow rate and collection efficiency 
 
 
Figure 18. The effect of different geometric parameters on the current-normalized flow rate. Most of the 
factors had no significant effect, with the exception of the length of the capillary showing a slight effect: the 
longer the length, the higher the flow rate/current.  DPC = how far the source capillary is inserted into the 
tissue. DAT = distance of the sampling capillary above the tissue. 
 
Figure 19. False color surface plot showing how larger molecular weight species can be collected via EOPPP 
despite having a large negative charge. A neutral species (z = 0) was used as a control. Molecular weights and 
charges are separated by a comma, e.g. 50, -1 means 50 g/mol, -1 charge. Source capillary i.d. = 200 μm 





Figure 20. (Left) Plot of mols/s as a function of time for three different applied currents in 
EOPPP. (Right) First derivative of the plot on the left. 
 
Figure 21. All concentrations (c) are expressed as % initial c in source capillary (c0). Both averages of c and 
Pé were measured in Pé  > 1 regions in the tissue. A) Average c at three different currents as a function of 
tissue thickness. Position 0 μm is the bottom surface of the tissue. 150 μm is the top surface. The source 
capillary tip is located at 110 μm. B) Average c as a function of X position (source tip → underneath sampling 
capillary). Source capillary tip is located at 600 μm. The i.d. of the sampling capillary span positions 650-750 






Figure 22. Plot of collection efficiency as a function of current and sampling i.d. Formation factor was held 
constant at fF = 0.2. For the sampling i.d. calculations, current was maintained at i = 10 μA. 
 
Figure 23. A) Cross section showing false color surface plot of pulsed concentration used to determine the 
residence or reaction time distribution. B-C) Plot of mols/s as a function of time for three different formation 
factors (fF, B) and three different currents (i, C). The weighted average residence times are 4.2, 4.8, and 5.3 s 
for fF = 0.1, 0.2, and 0.3, respectively. The weighted average residence times are 5.2, 3.7, and 3.0 s for i = 10, 






Figure 24. Plot of EO flow rate in the sampling capillary as a function of formation factor. 
 
Figure 25. (Left) Surface plot of Pé at different fF and two different currents. (Right) Line plot showing the 
Pé as a function of distance from the source capillary along the dashed line shown in Figure 12 of the main 
text. 
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2.5.4 Formation factor and internal standard 
 There is clearly an effect of local tissue environment on residence time and collection efficiency that we cannot control. However we can make sure these variations do not affect our measured quantities by normalizing all of the collected species to an internal standard (IS) for all sampling experiments. To demonstrate the efficacy of using an internal standard, we simulated a simple system with one substrate (YGGFL, S), one product (GGFL, P), one IS (yaGfl, IS), and one enzyme that obeys Michaelis-Menten kinetics (Vmax = 6 μM/s, Km = 50 μM). Figure 26 shows the concentration profile of all three species in the sampling capillary over the first 150 s of the perfusion for two different initial substrate (and corresponding internal standard) concentrations, 0.2 mM and 2.2 mM. Note that [S]0 = [IS]0 for both cases. Despite the fact that [S] remaining and [P] generated are different for the two conditions, two things are true: 1) the collected [IS]/[IS]0 in the source capillary are 
 
Figure 26. Evolution of the concentrations of substrate (S, blue), product (P, red), and internal standard (IS, 
black) over the course of 150 s of sampling. All concentrations are expressed as a percent of initial 
concentration of IS, [IS]0, in the source capillary. Two different substrate concentrations are shown: [S]0 = 
[IS]0 = 2.2 mM for [S]1 and [P]1, [S]0 = [IS]0 = 0.2 mM for [S]2 and [P]2. Vmax  = 6 μM/s, Km = 50 uM for 
both cases. i = 10 μA. 
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equal in both cases because the sampling conditions were identical, and 2) the sum of the [S]/[IS]0 and [P]/[IS]0 at steady-state equal the [IS]/[IS]0 at steady-state. The implications are that 1) the internal standard is sensitive to the sampling conditions and, consequently, the collection efficiency and thus can be used to normalize for any subtle changes due to tissue-to-tissue variability, and 2) the IS acts as a surrogate for the amount of exogenous substrate that could have been sampled if no enzyme reaction had occurred. The internal standard should ideally be as close in the primary sequence to the substrate of interest as possible (similar molecular weights and diffusion coefficients) and has all D-amino acid configuration to prevent hydrolysis by natural mammalian enzymes.  
2.5.5 Comparing calculated Vmax and Km vs. actual Vmax and Km 
An example is given for zero order kinetics. Analogous derivations can be made for other 
conditions. For zero order kinetics, the substrate concentration after a time, t, is 
0 max( )S t S V t= −            [10] 
Here, S0 is the initial substrate concentration in the source capillary, S*0. The experimentally 
measured quantity is the ratio of moles of substrate to internal standard, IS, the latter also being a 
surrogate for the initial substrate concentration (F is flow rate): 
0
( ) ( ) ( )S
IS
m F S t S t S t
m F IS IS S
⋅
= = =
⋅         [11] 
 
Now, we assume that the concentrations within the ECS are diluted by a factor, f. We denote the 
diluted concentrations with lower case. 
/ ; /s S f is IS f= =           [12] 
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In the tissue, the zero order reaction proceeds for time, t, so that the actual mole ratio is: 
max max max1 1S
IS
m s V t V t fV t
m is is IS
−
= = − = −         [13] 
As shown above, if the laboratory concentration, IS, is used to infer a value for Vmax from the 
experimentally measured ratio of moles of substrate to moles of internal standard, the inferred 
value will be greater than the true value by the dilution factor, f (a number greater than one). 
These derivations are summarized in Table 10. 
Table 10. Summary of the relationship between Vmax and Km in the ECS of the tissue and V’max and K’m 
derived from undiluted initial substrate concentrations (S0 or IS) for zero-order, first-order, and intermediate 
regimes. Lowercase p/is represents the moles of product to internal standard ratios in the ECS. 
Regime P/IS  p/is V’max/Vmax K’m/Km 
S0 << Km    
S0 ≈ Km    







Figure 27. Enzyme kinetics derived from fitting integrated Michaelis Menten equation to P/S0 values (A-C) or 
S/S0 (D-F) as a function of S*0. The results are summarized as correlation plots of either V’max vs. Vmax (A, 
D) or K’m vs. Km (B-C, E-F). We use primed quantities to denote the inferred enzyme kinetics from the 
fitting and to differentiate it from actual enzyme kinetics in the tissue ECS (no apostrophe). A) There are no 
significant differences in using time distribution or the average tR for estimates of V’max. The slopes of the 
V’max vs Vmax regression are 10.6 ± 0.3 and 11.3 ± 0.4 (± SE) when using time distribution and tR, 
respectively (the intercepts are not significantly different from zero). Moreover, the estimates of V’max are 
independent of the Km values. B-C) For regression analyses of K’m vs Km correlation plots, there are no 
significant differences between using the time distribution or the average tR for estimates of K’m at 
corresponding Vmax values ≤ 10 μM/s. The slopes are 2.8 ± 0.2 and 3.0 ± 0.6 for distribution and tR, 
respectively, and the intercepts are not significantly different from zero. However, for large values of Vmax 
(>10 μM/s), i.e. Vmax = 50 μM/s, there is significant intercept to the regression of K’m vs. Km and the 
magnitude of this intercept is Vmax-dependent. The regression equations for K’m vs. Km at Vmax = 50 μM/s 
are: K’m = (3.1 ± 0.2)*Km + (400 ±70 μM) (± SE) when the distribution was used and K’m = (3.5 ± 0.4)*Km + 
(1100 ±100 μM) when the first moment was used. This suggests that there is larger error in estimates of K’m 
when the first moment is used to estimate reaction time at large corresponding values of Vmax (>10 μM/s). 
Thus, for estimating K’m from the fitting, the entire time distribution should be used and if the 
corresponding Vmax is known, then either  a simple calibration factor can be used (for Vmax ≤ 10 μM/s) or a 
full regression equation needs to be used (for Vmax >10 μM/s). We then performed the same fitting to 
integrated Michaelis Menten using the S/S0 values instead of the P/S0 values. Interestingly, the correlation 
plots were nearly identical. This makes sense as we simulated only a single enzyme reaction. The only 
scenario in which fitting P/S0 or S/S0 would give different kinetics is if there is more than one reaction 
affecting the substrate, the product, or both. D) Slope of V’max vs. Vmax regression analyses: 11.2 ± 0.3 
(distribution) and 12.1 ± 0.4 (t = tR). E-F) Full regression equation for Vmax = 50 μM/s: K’¬m = (3.0 ± 
0.2)*Km + (240 ± 50 μM) (distribution) and K’m = (3.4 ± 0.4)*Km + (900 ± 100 μM) (t = tR). Slopes from 
regression of Vmax = 1-10 μM/s:  2.4 ± 0.3 (distribution) and 2.6 ± 0.6 (t = tR). All regression analyses were 
done in Stata SE 14.2. 
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2.5.6 Comparison of EO-driven and P-driven flow 
2.5.6.1 2D axisymmetric model 
 
 
Figure 28. 2-D axisymmetric calculations contrasting EO-driven (left) and P-driven (right) flow. The 
colored plot indicates magnitude of interstitial velocity, with red being the fastest and blue being the 
slowest. Red arrows indicate direction of velocity, not magnitude. The central ellipse (region 1, fF = 0.08) 
represent a region of higher tortuosity (λ) and smaller porosity (ε) than the surrounding porous medium 
(region 2, fF = 0.2). Region 1 is flanked on top and bottom by capillaries. Pressure gradient and electric 
fields were chosen such that the flow rates in the capillaries are equivalent in both cases (1.1 μL/min). ζcap 
is the zeta-potential of the capillary; ζtissue is the zeta-potential of the tissue. 
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Figure 28 shows the interstitial velocity profiles for a simple 2D axisymmetric model to directly compare and contrast the two different types of flow. This model has cylindrical symmetry with a region of higher porosity and lower tortuosity (region 2, ε = 0.4, λ = 1.4; fF 
= 0.20) enclosing an oblate spheroid of lower porosity and higher tortuosity (region 1, ε = 
0.2, λ = 1.6; fF = 0.08). We used the Kozeny-Carman equation to calculate permeability in a packed bed of particles: 
             [14] 
where dp is the particle diameter. We chose 10 μm for the particle diameter. In Figure 28, the red arrows show direction, but not magnitude, of flow. For pressure-driven flow (right), there is minimal flow in region 1 (dark blue), which is a region of low porosity and high 
tortuosity, and more flow around it. For EO flow (left), there is greater flow in region 1 (cyan) than in its pressure-driven counterpart. In fact, there is a nearly four-fold higher 
 
Figure 29. Line plot along the z-direction of the intersitial velocity (in mm/s) for EO-driven and P-driven 2D 
axisymmetric models in Figure 28. 
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flow rate in region 1 for EO flow than pressure-driven flow (~400 nL/min vs. ~100 nL/min), even though the average flow rates in the capillary are the same (1.1 µL/min) for 
the two models. This suggests that EO flow delivers more fluid to regions of small porosities and high tortuosities, regions that are less accessible to flow driven by pressure. In fact, the greater the difference in porosity and tortuosity between two neighboring 
regions, the more effective EO flow is at transporting than its pressure counterpart. A line plot comparing and contrasting the interstitial velocity through the axis of symmetry in 
Figure 28 can be seen in Figure 29. 
2.5.6.2 3D heterogeneous model In order to better demonstrate the efficacy of using EO over P-driven flow to deliver solutes, a 3D heterogeneous model was developed to compare and contrast mass transport through an anisotropic domain. In this model, an infusion capillary is placed in the cortex of the rat brain while a second sampling capillary is placed in the striatum. In order for collection to occur, the solutes need to transport across an anisotropic domain, the corpus callosum, which is a bundle of fibers stemming from the midline of the brain to both hemispheres. This structure results in low permeability perpendicular to the domain and high permeability parallel to the domain. In one simulation, fluid flow is driven by positive pressure in the infusion capillary and negative in the sampling capillary. In a second simulation, fluid flow is driven electrokinetically, by both electroosmosis and electrophoresis. In order to make direct comparisons and contrast possible, conditions for pressure and current were chosen such that flow rates in the capillaries were equal in both cases. 
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 Pressure boundaries were chosen such that the flow rate in the infusion capillary is 
comparable to that for electrokinetic CED (ECED). For an applied current of 75 μA and 100 
μm i.d. infusion and sampling capillary, the infusion flow rate is calculated to be 52 nL/min. For a comparable flow rate in the infusion capillary using pressure, a pressure difference of 
~6000 Pa is required (+3000 Pa at the infusion and -3000 Pa at the counter). Computational results are summarized in Figure 30. First of all, despite having the same 
flow rate in the infusion capillary, ECED infuses Ru(bpy)32+ into a larger volume of the brain in the same amount of time (t = 290 min) than its pressure counterpart. In the previous subsection, it was demonstrated that electroosmosis delivers more fluid and solute to porous media than its pressure counterpart. In this particular application, the infusion is further facilitated by electrophoresis, as the Ru(bpy)32+ molecule has a 2+ charge. Moreover, unlike pressure-driven flow, ECED is less dependent on the permeability 
 
Figure 30. 2D slice of a 3D geometry showing the evolution of tris(bipyridine)ruthenium(II) chloride 
(Ru(bpy)32+) over time for electrokinetically driven (top) and pressure-driven (bottom) convection enhanced 
delivery. The infusion capillary is located in the cortex while the sampling capillary is positioned benath the 
corpus callosum in the striatum. Red indicates high concentration while dark blue indicates low 
concentration. The color scale denotes actual concentration ranges in mol/m3. The corpus callosum (CC) is 
outlined in white dashed lines. 
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of a medium. The superficial electroosmotic velocity is independent of permeability in a homogenous medium at constant pressure (discussed in 2.3.2). However, due to the zeta potential mismatch that occurs between the infusion/counter capillaries (ζ = -46 mV)54 and the tissue (ζ = -23 mV)147, there is a pressure gradient that forms in the tissue between the two capillary tips. Specifically there is a positive pressure at the infusion/tissue interface and a negative pressure at the tissue/sampling capillary interface. This pressure gradient is dependent on the permeability and increases with increasing current (see 2.3.2). For an 




3.0  MEASURING EX VIVO AMINOPEPTIDASE ACTIVITY IN THE RAT 
HIPPOCAMPUS 
Reprinted with permission from ACS Chemical Neuroscience 2017 DOI: 
10.1021/acschemneuro.7b00326. Copyright (2017) American Chemical Society.  
 
With guidance from simulations in Chapter 2, it is possible to perform optimized experiments 
using EOPPP and analyze the data in order to obtain information about enzyme kinetics in intact 
tissue. It has been known for over a century that the hippocampus, the center for learning and 
memory in the brain, is selectively vulnerable to ischemic damage, with the CA1 being more 
vulnerable than the CA3. It is also known that Leu-enkephalin, or YGGFL, is neuroprotective. 
We hypothesized that the extracellular hydrolysis of YGGFL may be greater in the CA1 than the 
CA3, which would lead to the observed difference in susceptibility to ischemia. In rat 
organotypic hippocampal slice cultures, we estimated the Michaelis constant and the maximum 
velocity for membrane-bound aminopeptidase activity in the CA1 and CA3 regions. Using 
electroosmotic push-pull perfusion and offline capillary liquid chromatography we inferred 
enzyme activity based on the production rate of GGFL, a natural and inactive product of the 
enzymatic hydrolysis of YGGFL. We found nearly three-fold higher aminopeptidase activity in 
the CA1 than the CA3. The aminopeptidase inhibitor bestatin significantly reduced hydrolysis of 
YGGFL in both regions by increasing apparent Km. Based on propidium iodide cell death 
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measurements 24 hours after oxygen-glucose deprivation, we demonstrate that inhibition of 
aminopeptidase using bestatin selectively protected CA1 against delayed cell death due to 
oxygen-glucose deprivation and that this neuroprotection occurs through enkephalin-dependent 
pathways. 
3.1 INTRODUCTION 
According to the American Stroke Association160, ischemic stroke makes up approximately 87% 
of all stroke cases. It occurs due to obstruction of blood flow to the brain, resulting in oxygen and 
glucose deprivation. For over 130 years, it has been known that ischemia and other pathological 
insults result in damage to the hippocampus, the center of learning and memory4. The 
hippocampus responds selectively to these insults, with the CA1 region being the most 
susceptible to ischemic injury. This was first documented in a human patient in 19625 and 
demonstrated in transient ischemia models of rats and gerbils in the 1980s6,7, showing a time 
course of “delayed neuronal death.” This delay is marked by an initial onset of damage within 
the first 24 hours post-insult and results in maximum damage around 48-72 hours9. This allows 
for a window during which treatment can reduce or reverse the damage. There have been 
numerous molecular studies focused on excitotoxicity and abnormal calcium influx, oxidative 
stress and reactive oxygen species (ROS)10, as well as apoptotic processes and structural changes 
(reviewed in Dirnagl et al.11 and Schmidt-Kastner et al.12). Changes at the protein level have also 
been observed, including suppressed protein synthesis in the CA1 at 6 hours and 3 days post-
ischemia13,15,161 as well as post-translational modification, e.g. ubiquitination16, ROS-induced 
carbonyl modification17, and sumoylation18.  
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Despite the characterization of these events between initial onset of ischemia and 
subsequent acute and chronic effects, the exact mechanism behind the selective vulnerability of 
CA1 is not well understood. There is, however, some consensus that this vulnerability involves 
calcium-mediated processes12,19-21,162. The CA1, CA3, and dentate gyrus all exhibit increases in 
intracellular calcium 10 min after the initial onset of oxygen-glucose deprivation (OGD) in acute 
slices163. The CA1, however, displays a significantly higher level of intracellular Ca2+ than the 
other two regions. Mitani et al. found no differences in hypoxia-induced glutamate levels 
released to the extracellular space in the three regions164, suggesting that the differences in 
intracellular Ca2+ levels are not due to glutamate. However, the difference was eliminated in the 
presence of either nifedipine or verapamil, two L-type voltage gated Ca2+ channel (L-VGCC) 
antagonists163. Interestingly, opioid peptides, such as enkephalins and dynorphins, are thought to 
decrease Ca2+ levels by direct inhibition of L-VGCCs and indirect activation of K+ channels 
through activation of δ-opioid receptors (DORs)47,165. DOR expression has been found in both 
pyramidal and non-pyramidal cell types in the hippocampus41,42(reviewed in Gendron et al.)43 
and it has been suggested that DOR action is coupled to different second messengers at each 
site41. Zhang et al. demonstrated that DOR activation protects cortical neurons against glutamate-
induced injury49. Severe hypoxia has been shown to decrease endogenous YGGFL while 
hypoxic preconditioning increases both DOR mRNA and protein as well as reverses the 
reduction of YGGFL that was caused by severe hypoxia44,50. Preconditioning the neurons with 
opioid peptides prior to ischemia results in reduced brain infarct volume and improved 
neurological functions 24-hours post-occlusion in male rats51. Elevated endogenous opioid 
peptides had a similar effect on reducing infarct volume46. The range of  of DOR actions include 
1) maintaining ionic homeostasis, 2) inhibiting excitatory transmitter release, 3) increasing 
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antioxidants, and 4) regulating anti-apoptotic and pro-survival pathways, to name a few166. All of 
this evidence suggests that opioid peptides and DOR activation play crucial roles in protecting 
against ischemic damage.  
It is known that enkephalins are stored in large dense-core vesicles that are released 
extrasynaptically, resulting in volume transmission36-38. While there are numerous studies on 
enkephalins and their binding action at receptors such as DOR, the fate of opioid peptides once 
they are released into the ECS is less well known. Enkephalins, unlike many classical 
neurotransmitters (e.g. glutamate), are not limited by reuptake but solely by diffusion and 
extracellular degradation. Ectopeptidases are membrane-bound enzymes whose catalytic domain 
faces the extracellular space (ECS)68. These enzymes degrade active peptides, such as 
enkephalins, in the ECS, but recently it was revealed that they play a greater role in regulating 
peptide activities crucial to physiological function (reviewed in Konkoy et al. and Ou et al.)54,67. 
Not only that, but the activity of these enzymes can be altered as a result of either trophic or 
pathological triggers. Acute immobilization stress caused changes in enkephalinase and 
oxytocinase, two ectopeptidases that regulate anxiolytic peptides 66. Ischemic preconditioning, a 
neuroprotective treatment, restores the activity of two ectopeptidases that hydrolyze amyloid beta 
(Aβ), a toxic peptide implicated in Alzheimer’s disease72. Thus, ectopeptidase activity is a 
largely unexplored mechanism of neuropeptide control. Our group showed previously110 that 
exogenously-applied YGGFL is primarily hydrolyzed at the Tyr-Gly bond into GGFL in the rat 
hippocampus. Cleavage at this bond inactivates enkephalins167. There are two prominent 
ectopeptidases that cleave at the Tyr-Gly bond with high affinity for enkephalins in the rat 
hippocampus: aminopeptidase N (APN, EC 3.4.11.2) and puromycin-sensitive aminopeptidase 
(PSA, EC 3.4.11.14)168. We questioned whether or not the degradation of enkephalins, and thus 
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the ectopeptidase activity, is different between the different regions of the rat hippocampus. 
However, in order to best answer this question, we need tools that are capable of making enzyme 
measurements in their native state in the tissue. 
Traditional methods require homogenization of tissue and result in loss of any matrix 
information as well as all spatial and temporal resolution (reviewed in Ou et al.)54. In situ 
zymography was the first method to study localized enzyme activity in intact tissue 77,169-172. The 
limitation of this method, however, is the need for frozen brain sections rather than live tissue. 
Thus, there is a need for biochemical and biophysical tools to probe membrane-bound enzymes 
in their native, unperturbed states with adequate spatial resolution to study regional differences in 
enzyme activity. Our lab reported the first quantitative measurements of enzyme kinetics in live 
tissue based on the development of electroosmotic (EO) sampling107,110 from organotypic  
hippocampal slice cultures (OHSCs). OHSCs live on a membrane under which is growth 
medium. The growth medium can be replaced by a synthetic physiological fluid like artificial 
cerebrospinal fluid, aCSF. The aCSF can be augmented by peptide substrates. Fluid was drawn 
through OHSCs by the application of an external electric field, creating fluid movement via 
electroosmosis. Coupling EO sampling to an online microfluidic system, Wu et al. measured the 
apparent Michaelis constant (Km) and maximum reaction rate (Vmax) for sequential degradation 
of exogenous coenzyme A to cysteamine in OHSCs107. Xu et al. coupled EO sampling to 
capillary liquid chromatography with electrochemical detection and established Michaelis-
Menten parameters for aminopeptidase activity in whole-tissue OHSCs110. Interestingly, they 
found significant hydrolysis of exogenous YGGFL by a bestatin-sensitive aminopeptidase. 
Despite its successes, EO sampling lacked the spatial resolution required to determine the 
differences among the different regions of the hippocampus. Thus, a second capillary probe was 
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added to permit perfusion and sampling from specific regions of the hippocampal culture instead 
of sampling from the entire culture. This technique is called electroosmotic push-pull perfusion 
(EOPPP). Rupert et al. perfused the OHSCs with neuropeptide galanin and reported qualitative 
differences in galanin products in CA1 and CA3 using EOPPP followed by MALDI-
TOF/TOF111. No quantitative information on enzyme activity was reported.  
In this section of the dissertation, we report quantitative measurements of enzyme activity 
for hydrolysis of YGGFL to GGFL in the CA1 and CA3 regions of the rat hippocampus using 
EOPPP with offline capillary liquid chromatography (cLC), complemented with finite element 
method (FEM) calculations. We derived the values of Vmax and Km by fitting an integrated form 
of the classical Michaelis-Menten equation to both experimentally- and computationally-
determined parameters.  We found nearly three-fold higher activity of this enzyme in the CA1 
region. This observation led to the hypothesis that higher aminopeptidase activity may contribute 
to selective CA1 vulnerability to ischemic damage.  We tested this hypothesis using 20-, 30-, and 
40-min OGD (an ex vivo model for stroke) combined with cell-death analyses by propidium 
iodide staining. We found that inhibiting aminopeptidase activity with bestatin selectively 
reduced cell death in CA1 as a result of OGD. This neuroprotection was reversed by the δ-opioid 
receptor antagonist naltrindole. This is the first report of spatially resolved, quantitative enzyme 
activity using natural substrates in live tissue.  
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3.2 EXPERIMENTAL SECTION 
 
Organotypic hippocampal slice cultures. Dissection and culturing techniques were adapted 
from Gogolla et al.159 and approved by Institutional Animal Care and Use Committee (IACUC 
protocol #14021579) at the University of Pittsburgh. Briefly, the freshly decapitated heads of 
postnatal 7-day-old Sprague Dawley pups were disinfected by submersion in 70% ethanol prior 
to dissection. The hippocampi were removed and chopped along the septotemporal axis at a 
thickness of 350 μm (McIlwain, model TC752). Slices were immediately transferred to a Petri 
dish and incubated at 4 oC for 30 min prior to plating. The slices were separated under a 
 
 
Figure 31. A) Bright-field image of organotypic hippocampal slice culture. Sampling regions from the CA1 
and CA3 are circled. (B) Schematic showing the EOPPP process. The substrate YGGFL (LE in this figure), 
IS DYDAGDFDL, and fluorescent dye TR3 were passed through the culture via electroosmosis. (C) 
Chromatograms of calibration standard (black), CA1 sample (red), and CA3 sample (blue). Peaks were 
measured using UV detection at 214 nm. The major hydrolysis product was determined to be GGFL 
(indicated by arrows). GGFM, YGGFL, and IS peaks were also quantified. 
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dissection microscope using microspatulas. Slices with intact laminar structures were chosen for 
plating. To plate, 2-4 slices were placed onto a single porous (0.4 μm) modified PTFE insert 
membranes (Millipore) and cultured in a six-well plate (Sarstedt) with 95% air/5% CO2 
maintained at 36.5 oC. Culture medium is 50% opti-MEM (Gibco), 25% horse serum (Gibco), 
25% Hank’s balanced salt solution with phenol red (Life Technologies, 14025076), and 1% D-
(+)-glucose (Sigma Aldrich). The medium was changed every 2-3 days (every other day for 4 
cultures/well). The cultures can be kept alive ex vivo for up to 4 weeks (Figure 31A).    
Capillary liquid chromatography. High-pressure pumps, autosampler, column oven, and UV-
Vis detector are part of the Ultimate 3000 Nano LC system (Thermo Fisher). After samples were 
transferred to the autosampler vial (see sampling experimental section), they were injected onto a 
homemade capillary column (100 μm inner diameter (i.d.) x 1.7 μm particles, CSH-C18) and 
separated at 50 oC. Pump flow rate was 1.0 μL/min under isocratic conditions. Mobile phase 
composition was 20% acetonitrile (Fisher Scientific) in HPLC-grade water (Fisher Scientific) 
with 0.1% TFA. Absorbance measurements were made at 214 nm. Peak areas were measured 
from chromatograms in Chromeleon (Thermo Fisher). Using calibration curves, we converted 
the peak areas to concentrations. 
Analysis of cLC data. Calibration standards of YGGFL, IS, GGFM, and GGFL (1-10 μM for all 
except for GGFL, for which the concentration range was 0.1-1 μM) were injected between every 
sample for quality control and for quantitative analysis (Figure 31C). The degree of dilution of 
GGFM concentration was used to calculate the volume ejected from the sampling capillary. 
From there, we calculated the concentration of GGFL, substrate, and IS in the sampling 
capillary. The calculation is summarized by the following equation (using product GGFL as an 
example): 
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      [15] 
where P is the concentration of GGFL in the tissue after perfusion (not to be confused with P*, 
which is the concentration of GGFL in the sampling capillary), mGGFL is the moles of GGFL 
collected, Vt is the volume of ECS collected, Vs is the volume of the sampling capillary, Ueo is 
the flow rate during perfusion (L/min), ts is the total sampling time (in min), AGGFL is the peak 
area of GGFL from chromatogram (in  ), fGGFL is the calibration factor for GGFL 
peak (in ), AGGFM is the peak area of GGFM (in ), and fGGFM is the 
calibration factor for GGFM (in ). GGFMi and Vi are, respectively, the concentration 
and volume of GGFM solution in the autosampler vial prior to adding the sample from the 
sampling capillary. The concentration of substrate and IS in the tissue could also be calculated in 
a similar fashion. The final quantity reported was a concentration ratio of GGFL (or YGGFL) to 
IS in order to normalize for differences in collection efficiency (see next section). 
Fitting to integrated Michaelis-Menten equation. S*0 was varied (0.2, 0.4, 0.8, 1.2, 2.2 mM) 
while ‘t’ was held constant. Because the substrate is diluted in the tissue, we perfuse at the same 
time an internal standard at the same values of concentration as the substrate (IS = S0). From cLC 
chromatograms we obtain concentrations of YGGFL, GGFL, and IS collected at each S*0. We 
previously173 showed that normalizing all collected quantities to the IS allows for correction for 
collection efficiency due to tissue-to-tissue variations and, if the IS has similar diffusion 
coefficient to the substrate of interest (as it applies here), then it can also be treated as a surrogate 
for the amount of substrate that could have been collected if no reaction had occurred. Thus we 
divide the measured concentration of YGGFL and GGFL by the concentration of IS collected in 
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the sampling capillary to obtain S/S0 and P/S0, respectively. Ou et al.173 detail how to fit the 
integrated form of the Michaelis Menten (reproduced below) to the perfusion data P/S0 to obtain 
the best estimates of Michaelis Menten kinetics.  
       [16] 
All t-tests were done using the QuickCalcs software from GraphPad Software, Inc.  
Electroosmotic push-pull perfusion. Prior to sampling, cultures were incubated in medium 
with 7 μM propidium iodide (PI, Sigma Aldrich) for 24 hours to assess their health. Only healthy 
cultures were used for sampling. Sampling was performed as previously described (refer to 
Figure 31)111. In brief, the source fused silica capillary (200 μm i.d. x 30 cm, Polymicro 
Technologies) was pulled to a bee-stinger tip using a laser-based capillary puller (Sutter 
Instruments, Inc., model P-2000) and then cut to 15-20 μm i.d. The source and sampling (100 μm 
i.d. x 30 cm) capillaries (Polymicro Technologies) were filled with Hanks’ balanced salt solution 
(HBSS, with calcium, magnesium, without phenol red, Sigma Aldrich), mounted, and positioned 
using micromanipulators (Sutter Instruments, Inc., model MP-285) above a clean Petri dish 
(Corning Life Sciences) upon which the insert membrane and OHSC were placed. The other 
ends of the two capillaries (not in contact with OHSC) were submerged into two separate Petri 
dishes, each with 1.2 mL buffer and a Pt wire (Alfa Aesar). The Pt wires were connected via 
alligator clips to a high-voltage source (Stanford Research Systems, model PS350). The source 
capillary was filled with the substrate (YGGFL, American Peptide Company), internal standard 
(DYDAGDFDL, IS, GL Biochem Ltd), and Texas Red dextran 3kDa (Life Technologies). The 
source capillary was placed 60 μm below the OHSC surface at a 45o angle. The sampling 
capillary was placed 20 μm above the surface. We showed that the diagonal depth of source 
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capillary into the tissue (40-125 μm) and distance of sampling capillary above the tissue (14-60 
μm) have no effect on the flow rate. Perfusate consisted of fluorescent TR3 dye, YGGFL (0.2-
2.2 mM), and IS (0.2-2.2 mM). Perfusate solutions were made so that concentration of YGGFL 
and IS were the same for any given experiment. The current was turned on at t = 0 (Figure 31B). 
After 10 min of sampling the current was turned off, the sampling capillary was removed from 
the micromanipulator and the contents were pushed via insulin syringe (Fisher Scientific) into 10 
μL HBSS solution of 16 μM GGFM (BACHEM) with 0.1% trifluoroacetic acid (TFA, Sigma 
Aldrich). The collected sample was pipetted into a conical glass insert (Thermo Fisher Scientific) 
and placed into a glass autosampler vial (Chrom Tech, Inc.) for injection onto the cLC column. 
For initial substrate concentrations less than 400 μM, samples from 8 experiments were 
combined into one injection. For initial substrate concentration greater than or equal to 400 μM, 
4 experiments were combined. The sampling capillary was rinsed with 0.1 M NaOH between 
each sampling experiment to clean the capillary walls of any adsorbed residues. The base was 
rinsed out with additional HBSS. For inhibitor sampling experiments, all experimental 
conditions were the same as above, except 100 μM bestatin hydrochloride (Sigma Aldrich) was 
added to the bath underneath the cultures the night prior to sampling. This inhibitor was chosen 
based on OHSC sampling data from Xu et al.110. In the determination of Michaelis-Menten 
parameters with inhibitor, we only performed experiments at S*0 = 0.4, 0.8, and 1.2 mM. 
  
Oxygen-glucose deprivation and neuronal survival. Oxygen-glucose deprivation was done by 
submersion of OHSCs (up to four insert membranes at a time) in a nitrogen-purged, glucose-free 
buffer. A submersion chamber was fabricated in-house (Chemistry & Physics Machine Shop, 
University of Pittsburgh) that allows for perfusion of up to four insert membranes in a single 
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experiment (maximum 16 individual OHSCs). Glucose-free HBSS (125 mM NaCl (Fisher 
Scientific), 5 mM KCl, 2 mM CaCl2 (Fisher Scientific), 1 mM MgSO4 (Fisher Scientific), 25 
mM NaHCO3 (Fisher Scientific), 1.25 mM NaH2PO4 (Sigma Aldrich), 25 mM sucrose (Sigma 
Aldrich), pH 7.40) was prepared the day before experiment and warmed to 36 oC before use. 
Solution was poured into the submersion chamber and circulated using a variable-flow peristaltic 
pump (Fisher Scientific). The buffer was bubbled with N2 (Matheson). Dissolved O2 levels were 
monitored using DO110 portable dissolved O2 meter (Oakton Instruments). All components of 
the OGD chamber were placed into the humidified CO2 incubator to maintain the temperature 
throughout the experiment. Once O2 levels reached 0% (with 100% calibrated to O2 level in the 
ambient air), the OHSCs were secured into a 4-well platform (built in-house) and submerged in 
the bubbling buffer solution for 20, 30, or 40 min (depending on the condition). This time frame 
was chosen based on previous work by others69,174-176. Tissues that were treated with naltrindole 
were pre-incubated for 20 min and naltrindole was also added in the OGD solution. Immediately 
after the treatment, the dishes were returned to 6-well plate containing warm 36 oC culture 
medium with or without bestatin. Cultures were returned to the incubator for 2 hours and then 
exchanged for new medium containing PI. Cultures were imaged using the Leica TCS SP5 
confocal and multi-photon microscope 24 hours later. The Argon and DPSS561 lasers were used. 
The Argon laser was set to 25% power. The visible 561-nm wavelength laser was set to 15% 
power. Images were taken as 512 x 512 at 100 Hz with 5 line averages and pinhole size set to 
74.25 μm.  
Regions of interest were drawn around CA3 and CA1 areas of the hippocampus. Area of 
the regions was determined by area of visible damage (PI fluorescence) in positive controls, 
which were exposed to 200 μM NMDA (Sigma Aldrich) for 40 min. The same areas were drawn 
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for all experimental groups as well as negative controls. Exposure time was determined by the 
positive control fluorescence. Negative controls were not subjected to any treatment and were 
kept in the same incubator as the positive controls and OGD chamber. The incubator was 
maintained at 5% CO2 in air and 36 oC. The mean fluorescence intensity was measured. Cell 
death was measured as a percent . 
3.3 RESULTS AND DISCUSSION 
3.3.1 Sensitivity and selectivity 
In all EOPPP experiments, we perfuse cultures with a solution containing varying concentrations of the substrate YGGFL (S), a matching concentration of a peptidase-resistant internal standard, DYDAGDFDL (IS), and a fluorescent dye, Texas Red-modified 3kDa dextran (TR3) to visualize the process under a microscope.  Xu et al. showed that no hydrolysis occurs in the perfusate after peptides are extracted from the tissue using EO sampling, implying that the effect of soluble cytosolic peptidases in the extracted fluid is negligible110. Additionally, Rupert et al. showed that EOPPP causes minimal cell death in the surrounding tissue under certain conditions139. We employed these conditions here.  
Using EOPPP, we perfused the CA1 and CA3 regions of OHSCs (see Figure 31) with varying concentrations of S and IS. Perfusion at each concentration of substrate was performed at least eight times. We found the major hydrolysis product of YGGFL to be 
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GGFL in the rat hippocampal slice culture, in agreement with previous findings by us110 and others177. We wanted to assess how selective the determination of aminopeptidase activity on YGGFL in tissue cultures is by determining the ratio of the sum of YGGFL and GGFL concentrations in collected perfusate to the initial concentration of substrate YGGFL. The IS has a similar diffusion coefficient to YGGFL but it is not hydrolyzed enzymatically. Thus the collected IS concentration represents the concentration of YGGFL that would have been collected in the absence of enzyme activity. It accounts for the dilution experienced by the electroosmotically introduced substrate solution as well as substrate loss by diffusion away from the sampling capillary. It is used as a surrogate for the initial substrate concentration exposed to the enzymes in the tissue, S0. We perfused CA1 and CA3 regions in cultures at various initial YGGFL and IS concentrations in the presence and absence of the inhibitor bestatin. The hypothesis is that if the sum of the concentration of the product, P, plus the remaining substrate, S, was a significant fraction of the concentration of IS collected ((S+P)/S0) and that fraction was independent of the presence of the inhibitor bestatin, then we could use the measurement to assess differences in aminopeptidase activity in CA1 and CA3.  
EOPPP was carried out in CA1 and CA3 using a range of initial concentrations in the source capillary, which we denote S*0 from 0.2 to 2.2 mM. The asterick differentiates this 
term from the initial concentration in the tissue ECS, S0. We found that the average (S+P)/S0 is 69.6 ± 0.5% for this S*0 range with no inhibitor treatment. This is in agreement with the prior work cited above. In order to assess the dependence of ((S+P)/S0) on inhibitor, we pooled all of the data together (two regions, five S*0, and with/without 
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inhibitor) and carried out a linear regression of the observed measurements of (S+P)/S0 on the categorical variables “Region” (CA1 = 0, CA3 = 1), “Inhibitor” (absence = 0, presence = 1), and the continuous variable S*0 (0.2, 0.4, 0.8, 1.0, and 2.2 mM). Because the data also seemed to show that the dependence of ((S+P)/S0) on S*0 was dependent on region, we used the product ‘region x S*0’ as another independent variable. Table 1 summarizes the results of the regression. 
Table 11. Summary of regression statistics. 
 Coefficient Std. Error t value p value 
Intercept 0.36 0.05 7.14 2.97 x 10-9 
Region 0.31 0.07 4.45 4.55 x 10-5 
S*0 0.32 0.04 7.19 2.44 x 10-9 
Inhibitor -0.02 0.04 -0.51 0.610 
Region x S*0 -0.26 0.07 -3.89 2.83 x 10-4 
 
Regression results for CA3 (Eqn. 17a) and CA1 (Eqn. 17b) can be summarized by two 
equations: 
((S+P)/S0) = 0.65 + 0.06 S*0     [17a] 
((S+P)/S0) = 0.36 + 0.32 S*0     [17b] 
There are several observations to be made from this analysis. Foremost, the presence of 
the inhibitor does not significantly affect ((S+P)/S0). In addition, for S*0 values near 1 mM the 
sensitivity to aminopeptidase activity is high, as in both CA1 and CA3 the fraction of YGGFL 
hydrolyzed to the product GGFL is on the order of 70%.  On the other hand, at the lowest value 
of S*0, 0.2 mM, while the CA3 region still maintains a reasonable ratio of ((S+P)/S0) of 66%, in 
the CA1 is only 42%. As a result, in the determination of Michaelis-Menten parameters, we did 
not use the data for S*0 = 0.2 mM in the CA1.  
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The fact that the presence of the inhibitor does not significantly affect the ratio ((S+P)/S0) 
means that the remaining 30% of the total activity is due to a bestatin-insensitive enzyme or 
enzymes. This remaining activity could be due to an enzyme that cleaves the substrate YGGFL 
at a different site (such that GGFL is not produced) and/or an enzyme that cleaves GGFL into 
smaller fragments. Because the ratio P/S0 is more selective for the activity of the bestatin-
sensitive aminopeptidase than the ratio of S/S0, we primarily focus on Michaelis-Menten 
parameters derived from the former ratio than the latter ratio. It is true, however, that despite 
quantitative differences, the qualitative conclusions drawn from examining P/S0 and S/S0 
measurements are the same (to be discussed in the next section).   
3.3.2 Differential aminopeptidase activity in the hippocampus 
Using the Lambert W code in Matlab R2015b we derived apparent Vmax and Km,  V’max and K’m, 
for each region from fitting the integrated Michaelis-Menten equation (Eqn. 16 in the 
 
 
Figure 32. Plots of P/S0 as a function of S*0 for both CA1 (blue) and CA3 (red) regions. Experimental values 
are shown as scatter plots with error bars (SEM) and predicted values from the integrated Michaelis Menten 
function are shown as dashed lines.  
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Experimental section) to P/S0 vs S*0 (Figure 32). The results from the fit are summarized in 
Table 2. The term “apparent” here is not the same as that used in Chapter 1.4.1. “Apparent” used 
previously referred to the fact that the enzyme kinetics was for an overall reaction comprised of 
multiple steps. The “apparent” here refers to the observed kinetics before dilution of initial 
substrate concentration has been taken into account. We distinguish these maximal rates and 
Michaelis-Menten constants with a prime because they were derived using S*0, the initial 
laboratory concentrations of the substrate (in the fill solution of the source capillary), as opposed 
to actual substrate concentrations in the tissue. We showed using in silico experiments173 that 
both the substrate concentration and local velocities vary within the interrogated region. 
Fortunately, despite this complexity, the actual Vmax and Km in the tissue ECS are related to the 
inferred V’max and K’m from the fitting by simple calibration factors. In fact, Vmax and Km in the 
tissue ECS can be obtained by dividing the V’max and K’m by 10.6 ± 0.3 and 2.8 ± 0.2 (mean ± 
SE), respectively173. The values of V’max and K’m as well as Vmax and Km are summarized in 
Table 2.  
Table 12. Michaelis-Menten parameters in CA3 and CA1 regions of the rat hippocampus (mean ± SEM), 
derived from fitting the integrated Michaelis Menten to the P/S0 perfusion data.  
Region V’max (μM/s) Vmax (μM/s) K’m (mM) Km (μM) 
CA3 33 ± 6 3.1 ± 0.6 0.2 ± 0.1 70 ± 40 
CA1 90 ± 10 9 ± 1 0.4 ± 0.2 100 ± 70 
As seen in Table 2, the Vmax in CA1 is nearly three-fold higher than that in CA3. Since 
Vmax is the maximum rate of reaction, this indicates that a higher level of aminopeptidase activity 
is present in the CA1, which could indicate a higher concentration of enzymes and/or a more 
active isoform of the enzyme. This regional difference was significant with a p-value < 0.0001 
(one-tailed t-test). There was no significant difference between the values for Km, however (p = 
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0.14, two-tailed t-test). Interestingly, Km values in both regions are comparable to that of APN 
reported in the literature (45-60 μM)167.  
In order to characterize the aminopeptidase, we incubated the OHSCs with 100 μM of the 
aminopeptidase inhibitor bestatin prior to sampling. Xu et al. demonstrated previously that it was 
the only inhibitor in a set of inhibitors that significantly decreased the production of GGFL from 
YGGFL in OHSCs110. As described above, experimental P/S0 and S*0 were used with the 
integrated Michaelis-Menten equation (Eqn. 16) to determine V’max. Because bestatin is known 
to be a competitive inhibitor, the integrated Michaelis-Menten is similar to Eqn. 16 with the 
exception that K’m is replaced by K’mapp. By fitting the integrated Michaelis-Menten equation to 
the inhibitor data for both regions, we determined the values for K’mapp. Given that the 
calibration factor of K’mapp/Kmapp is 2.8 ± 0.2173, we can obtain Kmapp accordingly. Furthermore, 
because we know Km from our data without the inhibitor, we can determine Ki for the two 
regions by using the simple relationship . These results are summarized in 
Table 3. The amount of GGFL was significantly reduced compared to amount of IS collected. 
Bestatin inhibited aminopeptidase activity in both CA1 and CA3 regions of the rat hippocampus 
during the sampling experiments by dramatically increasing the Michaelis-Menten constant from 
100 ± 70 μM to 1.0 ± 0.2 mM in the CA1 and 70 ± 40 μM to 0.6 ± 0.2 mM in the CA3. The 
Kmapp and Ki values for the two regions are not significantly different (p = 0.31 and 0.43, 
respectively, two-tailed t-test). Interestingly, the Ki values, although accompanied by significant 
uncertainty, are comparable to the Ki of bestatin for APN reported in the literature (4 μM)167. 
Table 13. Kmapp in both CA1 and CA3 after addition of the inhibitor bestatin (mean ± SEM). 
Region K’mapp (mM) Kmapp(mM) Ki (μM) 
CA3 + bestatin 1.7 ± 0.5 0.6 ± 0.2 11 ± 7 
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CA1 + bestatin 2.7 ± 0.5 1.0 ± 0.2 12 ± 9 
As mentioned in the introduction, the most prominent ectopeptidases that cleave at the 
Tyr-Gly bond with high affinity for enkephalins in the rat hippocampus are APN and PSA168. 
Autoradiographic profiling showed moderate to high labeling of APN in the hippocampus178. 
PSA and APN have similar Km for YGGFL (32 μM, 45 μM, respectively)167,179. PSA is highly 
sensitive to both puromycin (Ki = 1 μM) and bestatin (Ki = 0.5 μM) while APN is significantly 
more inhibited by bestatin (Ki = 4 μM) than puromycin (Ki = 100 μM)167. Previous work in our 
group showed little to no effect of puromycin on hydrolysis of exogenously applied YGGFL in 
whole OHSCs110. We demonstrate here that the Km of the bestatin-sensitive aminopeptidase 
activity in both CA3 and CA1 are comparable to that of APN and the Ki we derive from inhibitor 
experiments for both regions are comparable to that of bestatin for APN, as reported in the 
literature. This combination of results suggests that a significant contribution to the activity we 
see in both hippocampal regions is from APN.  
Fitting integrated Michaelis Menten equation to complementary S/S0 data yielded 
interesting results (see Table 14 in Appendix B). In contrast to the results based on P/S0, which 
showed a ~three-fold higher activity in the CA1 than the CA3, the activity in CA1 is ~two-fold 
higher than that of CA3 (p = 0.0045). This is due to the fact that the three-fold difference in 
aminopeptidase activity is “diluted” by the activity of other enzymes present.  Vmax in both 
regions are significantly higher than those derived using P/S0 in Table 2 (p < 0.0001 for CA3 and 
p = 0.0037 for CA1). This is consistent with the hypothesis that there is an additional enzyme or 
enzymes hydrolyzing YGGFL at sites other than the Tyr-Gly bond. Km values were not 
significantly different from those derived from P/S0 data (p = 0.48 for CA3 and p = 0.88 for 
CA1); however, Km values are significantly different (p < 0.0001) between the two regions. Based on this data, we hypothesize that the “missing” 30% in the (P+S)/S0 ratio may be due 
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to membrane-bound neutral endopeptidase (NEP, enkephalinase, neprilysin, CD10, EC 
3.4.24.11) and/or angiotensin converting enzyme (ACE, EC 3.4.15.1). NEP has moderate expression in the hippocampus180, has good affinity for YGGFL (Km = 74-200 μM)181, cleaves it and its product GGFL at the Gly-Phe bond, and is bestatin-insensitive. Similarly, ACE also cleaves at the Gly-Phe bond. EO sampling data from Xu et al. semi-quantitatively showed 
that a cocktail of thiorphan (selective NEP inhibitor), captopril (ACE inhibitor), and GEMSA (carboxypeptidase inhibitor) increased the GGFL peak by 2-fold relative to the IS110. Since carboxypeptidases have low affinity for peptides with C-terminal leucines according to the 
MEROPS database, this is indirect evidence NEP and/or ACE may contribute to the missing 30%. We focus here on membrane-bound peptidases because we demonstrated before110 that incubation of the collected sample at room temperature for 45 min did not change, quantitatively or qualitatively, the outcome compared to samples quenched with acid immediately after collection. This makes it unlikely that there is hydrolysis by soluble enzymes contributing to the observed outcome.  
3.3.3 Neuroprotection from aminopeptidase inhibition  
After we observed higher aminopeptidase activity in the CA1, we wondered whether or not this higher activity contributes to the selective damage of the CA1 to ischemia. Recall that enkephalin acting through the DOR are neuroprotective during ischemia. It has been suggested that ectopeptidases are required to maintain a tight control of the level of opioid peptides182. Although literature on the neuroprotective effects of DOR and enkephalins is 
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extensive, there is little discussion on the role of the ectopeptidases that hydrolyze enkephalins in 
neuroprotection. Ansorge et al. showed that the use of synthetic APN inhibitor actinonin 
significantly reduced cell death of the CA1 pyramidal neurons69. They did not examine effects of 
APN inhibition on the other subregions of the hippocampus nor did they explore why this 
neuroprotection occurred. Moreover, opiorphin, a naturally-occurring antidepressant in humans, 
protects enkephalins from degradation by APN183,184 and elicits antidepressant-like effects by 
activating endogenous δ-opioidergic pathways184. Thus, we questioned 1) whether the higher 
aminopeptidase activity that we observed in the CA1 may contribute to selective CA1 
vulnerability to ischemic damage because of faster hydrolysis (and deactivation) of 
neuroprotective peptides in that region, and 2) whether the neuroprotection occurs through 
enkephalin-dependent pathway. We thus performed a series of imaging experiments to explore 
whether inhibiting aminopeptidase activity protects CA1 and/or CA3 against ischemic damage 
following 20-, 30-, and 40-min OGD. Fluorescence from the DNA intercalator propidium iodide 
(PI) was used as a cell death marker. All cell death is reported as (as a %), where F is 
the fluorescence intensity of samples, F+ is the fluorescence intensity of NMDA-treated cultures, 
and F- is the fluorescence intensity of negative controls (no treatment). 
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First of all, in agreement with literature185, there is higher cell death in the CA1 than the 
CA3 for longer OGD times (p = 0.038, 0.011 for 30-min and 40-min OGD respectively, one-tail 
t-test, Figure 33F-G). There is no significant difference in cell death between the two regions at 
20-min OGD (p = 0.15, one-tail t-test, Figure 33E). We found that addition of bestatin 
immediately after OGD significantly decreased cell death in the CA1 for all OGD durations (p = 
0.032, 0.035, 0.032 for 20-, 30-, and 40-min OGD, respectively, one-tail, Figure 33E-G). These 
results support the first hypothesis that higher aminopeptidase activity in the CA1 may contribute 
to selective CA1 vulnerability to ischemic damage because of faster hydrolysis (and 
deactivation) of neuroprotective peptides in that region. We did not observe any effect of bestatin 
 
 
Figure 33. A) Propidium iodide (PI) fluorescence for positive control (200 μM N-methyl-D-aspartic acid, 
(NMDA) and negative control (NEG), B) PI fluorescence after 20-min oxygen-glucose deprivation alone 
(OGD), OGD and incubation with 100 μM bestatin immediately after (BEST), OGD and incubation of 
cultures with 10 μM naltrindole hydrochloride  20 min prior to OGD as well as during OGD (NAL), and 
OGD with both bestatin and naltrindole incubation (BEST + NAL), C) same as B) except for 30-min OGD 
condition, D) same as B) except for 40-min OGD condition, E-G) % cell death for the different conditions 
mentioned previously for 20-, 30-, and 40-min OGD conditions, respectively.  All images were taken on the 
Leica TCS SP5 confocal and multiphoton microscope. *p < 0.05, **p < 0.01, ***p < 0.001. 
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administration on CA3 neuronal cell death compared to OGD treatment alone (p = 0.11, 0.32, 
0.18 for 20-, 30-, and 40-min OGD, one-tail). Literature searching revealed no reports of 
enkephalins or enkephalin-derivatives rescuing the CA3 region from ischemic damage, which is 
consistent with our findings. 
Secondly, because aminopeptidase N is not a selective enzyme and has numerous natural 
substrates, including angiotensin III, both Leu- and Met-enkephalin, substance P, and bradykinin, 
we wanted to determine whether or not the neuroprotection from bestatin administration is from 
an increase in enkephalin lifetime. Both Leu- and Met-enkephalin have high affinities for DOR, 
a ten-times lower affinity for the mu opioid receptor and negligible affinity for the kappa opioid 
receptor186. An enkephalin analog [D-Ala2, D-Leu5] administered post-transient forebrain 
ischemia is neuroprotective to hippocampal CA1 neurons and this neuroprotection was reversed 
using naltrindole187, a selective DOR antagonist188. We hypothesize that the bestatin-induced 
decrease in cell death from OGD in the CA1 occurs through an enkephalin-dependent pathway, 
thus a selective DOR antagonist should reverse this neuroprotective effect. Co-administration of 
naltrindole with bestatin increased the cell death observed in the CA1 neurons relative to those 
treated with bestatin alone for all three OGD durations (p = 0.0001, 0.038, 0.0012 for 20-, 30-, 
and 40-min OGD, respectively, one-tail). We conclude that the effect of bestatin is most likely 
caused by an increase in enkephalin steady-state concentration in the extracellular space in CA1. An important caveat is that we measured enzyme activity pre-deprivation and not post-deprivation. Others have demonstrated using immunohistochemistry, RT-PCR, and protease activity assays that aminopeptidase N is upregulated in the frontal, temporal, and occipital cortices from 6 hrs to 7 days post ischemia189. Since this study did not look at subregional differences in the hippocampus, it is unknown whether or not the CA1 and CA3 
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had different degrees of upregulation. We do not think this changes the conclusion in this paper. 
Interestingly, administration of naltrindole without co-administratrion of bestatin 
increased cell death relative to OGD only for 30-min OGD (p = 0.042, one-tail, Figure 33F) but 
not for shorter (20-min, p = 0.11) or longer (40-min, p = 0.80) ischemic insults. The time 
dependence of this naltrindole effect is unexpected. Several factors contribute to the observed 
effect of the antagonist.  After shorter (20-min) ischemic insult, which is considered a mild form 
of ischemia for OHSCs and is often used as a preconditioning paradigm50, there are increases in 
both DOR mRNA and protein as well as Leu enkephalin levels50. On the other hand, Leu-
enkephalin levels50, DOR mRNA and protein50,190,191 are suppressed after severe ischemia. The 
latter seems at odds with the observations that enkephalin administration post-ischemia rescues 
the CA1 pyramidal neurons187. The DOR system is both dynamic and responsive to its 
environment. Agonist binding to DORs results in internalization of the ligand/receptor complex, 
which leads to enhanced receptor recycling and resensitization (receptor reactivation) in an 
agonist-specific manner192 (reviewed by Gendron et al.43). Clearly, more work is required to fully 
understand the time-dependence of the effect of a DOR antagonist on neuroprotection in the 
hippocampal formation43. 
Based on these results, we propose that the three-fold higher aminopeptidase activity in 
the CA1 results in significantly shorter lifetime of neuroprotective endogenous opioid peptides in 
the ECS of the CA1 region compared to that in the CA3. The shorter lifetime of these peptides in 
the ECS decreases their effectiveness to activate the DOR reducing neuroprotection. The 
inhibitor bestatin reduces the aminopeptidase activity in the CA1 such that the steady-state 
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concentration of enkephalins are higher in the ECS, increasing activation of DORs, consequently 
reducing cell death in the CA1 following OGD. 
3.4 CONCLUSIONS 
We have measured for the first time quantitative differences in membrane-bound aminopeptidase 
activity in different regions of organotypic hippocampal cultures using a novel EOPPP-cLC 
method. The difference in aminopeptidase activity was the motivation to carry out further 
experiments to determine whether this difference might contribute to the differential 
susceptibility of CA1 and CA3 pyramidal neurons to OGD. Indeed, it does. Bestatin at all three 
OGD durations decreases neuronal damage in the CA1 region but has no effect in the CA3. This 
effect is likely due to the increase in steady-state extracellular concentration of enkephalins 
which leads to neuroprotection via the DOR. The method not only opens doors to understanding 
membrane-bound enzyme activities in their native environment but also allows for answers to 
some important, long-standing neurochemical and biochemical questions that have been 
unanswered due to lack of appropriate tools. 
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3.5 SUPPORTING INFORMATION FOR MEASURING AMINOPEPTIDASE 
ACTIVITY  
3.5.1 Enzyme kinetics derived from S/S0  
Table 14. Enzyme kinetics derived from fitting integrated Michaelis-Menten equation to S/S0 vs S0 data 
(mean ± SEM). 
Region V’max (μM/s) Vmax (μM/s) K’m (mM) Km (μM) 
CA3 100 ± 10 9 ± 1 115 ± 1 41 ± 3 
CA1 170 ± 20 16 ± 2 267 ± 2 95 ± 7 
3.5.2 % cell death from propidium iodide experiments 
Table 15. Summary of % cell death for all experimental groups in both regions of hippocampus. 
  20 min-OGD 30-min OGD 40-min OGD 





24 ± 2 
20 ± 3 
26 ± 8 
34 ± 6 
40 ± 4 
35 ± 10 
45 ± 9 
50 ± 9 
52 ± 5 
42 ± 9 
63 ± 20 






26 ± 3 
20 ± 2 
34 ± 6 
40 ± 2 
58 ± 8 
35 ± 9 
82 ± 10 
54 ± 5 
84 ± 12 
44 ± 9 
67 ± 9 
87 ± 6 
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3.5.3 Control experiments 
 
 
Figure 34. % cell death naltrindole only without any OGD 
conditions. Naltrindole itself does not cause significant 
damage. 
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4.0  THE USE OF ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY TO 
MEASURE FORMATION FACTOR IN THE BRAIN 
The last part of this dissertation covers ongoing work using electrochemical impedance 
measurements to understand the formation factor of the brain, which, as previously mentioned, is 
important in understanding the mass transport. This method utilizes carbon fiber microelectrodes 
coated with poly(3,4-ethylenedioxythiophene)/carbon nanotubes for a high charge storage 
capacity compared to bare electrodes. 
4.1 INTRODUCTION 
The neurons and glial cells of the brain exist in a jelly-like150 extracellular matrix that resembles 
a porous medium. The extracellular space, or the fluid-filled space between the cells, has a foam-
like structure193 with characteristics that affect mass transport such as in volume transmission of 
neurotransmitters. Monitoring neurotransmitters in the brain extracellular space using implanted 
probes have provided valuable information about brain function and pathology (see 
Introduction). One of the most popular methods for measuring neurotransmitter concentration in 
the ECS is microdialysis88 (reviewed in Ou et al 2014}. Since its advent in the 1970s, it has 
become the gold standard in the field of sampling194 due to not only its ability to sample a variety 
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of molecules such as amino acids, neuropeptides, and hormones but also its ability to introduce 
drugs and substrates into the tissue of interest via retrodialysis.    
 
While many think of processes such as degradation and reuptake in affecting the mass 
transport of neurotransmitters in the ECS, the structure of the ECS itself also plays a significant 
role in the efficacy of the neurotransmission (Figure 35). The structure of the ECS can change 
with various factors, including brain region150, disease195, age196, and environment, such as the 
osmolarity of the solution149 and the presence of any implanted devices. Along the lines of this 
latter issue, several early studies in the field raised concerns about the perturbation of the 
microdialysis probe on tissue health and whether or not it was affecting the amount of 
neurotransmitter collected. It is known, for instance, that the probe (~300 μm in diameter) is 
significantly larger than neurons and glia (5-100 μm diameter)197, myelinated fiber bundles (0.2-
2 μm)197, as well as the spacing between blood vessels (50 μm)194. Emerging evidence suggests 
that penetration injury from probe insertion into living brain tissue leads to an inflammatory 
 
Figure 35. Schematic showing the different processes a neurotransmitter (red dot) can encounter in the 
extracellular space of the brain, including degradation by ectopeptidases and reuptake. The geometry of the 
ECS also plays a role in the mass transport of the neurotransmitter to its target action, such as binding to a 
receptor.  
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response called the foreign body response104. During this event, implantation of the neural probes 
such as microdialysis probes results in injury to the vasculature and disruption of the blood-brain 
barrier (BBB) 100,198,199, activation of microglia and astrocytes100,200, inflammation201, oxygen 
deprivation100,194,200, and neural degeneration104. Not only that, but the activation and 
proliferation of glial cells around the probe, called gliosis, results in a diffusion barrier for 
analytes of interest to reach the probe, affecting the concentration measured101,202. Efforts have 
been made to mitigate this foreign body response using pharmacology, such as the synthetic, 
highly potent glucocorticoid dexamethasone101-105. The majority of the studies monitoring the 
detrimental effects are often perturbing the environment themselves or are just downright 
destructive, such as the need to isolate the tissue samples, fix, and perform antibody treatment for 
imaging studies. Moreover, while recent advances in in vivo microscopy have been extremely 
powerful in revealing immediate microglia reaction to implanted probes200, even two-photon 
microscopy is limited by penetration depth in the brain and thus cannot access deep-brain 
structures.  
The lipid bilayer of the plasma membrane acts as a capacitor at low frequencies (~10 kHz 
and lower) of alternating current (AC), but at high frequencies (1 MHz), the capacitance 
contribution of the cell membrane decreases and current can pass through both extracellular and 
intracellular compartments203. Gardner-Medwin pointed out204 that under the assumption that 
current is confined to the ECS, the resistivity of the brain is proportional to λ2/ε, which is the 
inverse of the ‘formation factor,’ a geological term relating conductivity in free media to that in 
porous media205. Herein, we will focus primarily on conductivity because the formation factor, 
the quantity of interest, is directly proportional to conductivity. It should be noted that the 
majority of literature uses resistivity instead but the two terms are reciprocals. Electrical 
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impedance spectroscopy (EIS) is a technique that can characterize tissue based on its electrical 
properties. A small sinusoidal AC excitation potential is applied to the cell of interest and the 
current is measured. Oftentimes equivalent circuit modeling is used to extract the appropriate 
impedance. Different driving frequency can be used to tune into different behavior; for example, 
the range 1 kHz – 1 MHz is often called the β-dispersion region203 and is ideal for investigating 
the electrical properties of the ECS. The higher frequencies in this range can be used to study 
intracellular electrical properties as well. Since its advent more than six decades ago, 
electrochemical impedance measurements of living tissue have been used extensively for 
medical technology, physiological research, and clinical diagnosis206. The first application of 
impedance measurements in vivo was to examine myocardial function207. Researchers have measured conductivity differences between white vs. gray matter208, due to neural activity209, as well as changes in conductivity due to hypothermia210, penetration injury211,212, hypoglycemia213, ischemia214-216, seizures217-219, spreading depression218,220,221, and stroke222.  EIS has been used for a wide range of medical applications223-225 as well as being used to characterize electrodes226-228 and measure tissue encapsulation around implanted probes212,229,230. Unlike the other methods, impedance measurements do not require 
a well-chosen probe molecule. One limitation, however, is that because the conductivity in 
porous medium relates to conductivity in free medium via the formation factor, which is a 
function of both ε and λ, the two terms cannot be differentiated. However, in many instances, 
changes in λ are small so changes in conductivity will predominantly reflect changes in ε134. The benefit of conductivity measurements via are two-fold: 1) they provides structural information that would be obtained with an ideal point molecule and 2) these measurements are instantaneous134.  
 97 
We are interested in developing a rapid and sensitive method for measuring changes in the ECS 1) with high spatiotemporal resolution, 2) without the technique itself causing injury to the brain, and 3) be applicable for chronic implantation to monitor processes over a long period of time. Specifically, we are interested in the timeline of glial scar formation around a microdialysis probe and how this scar affects the formation factor and, consequently, mass transport in the ECS. To do this, we utilize 400 μm long x 7 μm i.d. carbon fiber microelectrodes coated with poly(3,4-ethylenedioxythiophene)/carbon 
nanotubes (PEDOT/CNT) for EIS measurements. PEDOT is a conducting polymer used for chronically implanted neural prosthesis due to its excellent electrochemical stability and compatibility with various electrolytes231-234. PEDOT coatings can be readily deposited onto electrode surfaces using electrochemical deposition198,231,235,236 and significantly increases charge storage capacity compared to bare electrodes237-241. PEDOT is often doped with carbon nanotubes (CNTs), which provides additional structural support, reduced astrocyte activation, and increased local neuron density242. Recording devices coated with 
PEDOT/CNT were implanted for at least 12 weeks in mice primary visual cortex228. These are all important criteria for minimizing perturbation to the tissue environment and increasing the lifetime of the electrodes, especially for chronic implantation. Furthermore, 
because of the small size of the electrodes relative to those previously used for EIS, it should not disrupt the vasculature. In this chapter, we demonstrate the sensitivity of the method to changes in the conductivity due to the presence of borosilicate beads, which is our in vitro brain surrogate. We also demonstrate the sensitivity of this method in detecting changes in formation factor as the electrode is implanted deep inside the rat brain. In order to accurately extract the conductivity of the surrounding medium around the working 
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electrode, we developed an equivalent circuit model that takes into account the shunt capacitance and the coating. 
4.2 EXPERIMENTAL SECTION 
 
Microelectrodes. The experiments used a three-electrode cell, with a carbon fiber microelectrode as the working electrode, a Ag/AgCl reference electrode, and either a stainless steel bone screw (in vivo, Fisher Scientific) or Pt wire (in vitro, Alfa Aesar) for counter electrode. Single carbon fibers (7 μm i.d., T650, Cytec Carbon Fibers LLC) were threaded through pulled (Narishige) borosilicate capillary (0.58 mm i.d., 1.0 mm o.d., Sutter Instruments). They were sealed with a low viscosity epoxy (Spurr Epoxy, Polysciences Inc.), cured overnight at 72 oC, and trimmed to 400 μm with scalpel blade under a dissection microscope. The capillaries were completed by filling them with Hg (Sigma Aldrich) and a single Nichrome wire was inserted into each electrode. Prior to use, electrodes were soaked for 10 min in isopropyl alcohol (Fisher Scientific) to clean the electrode surfaces.  
PEDOT/CNTs. Carbon fiber microelectrodes were coated with PEDOT/CNT (Figure 36) within 24 hours of in vivo experiments. CNTs were functionalized according to previous reports228. In brief, CNTs were soaked in concentrated nitric and sulfuric acids in 1:3 volume ratio, respectively, sonicated, and rigorously stirred overnight at room temperature. The carboxylated CNTs form a precipitate and crash out of solution. The 
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solution was then centrifuged at 16 kr/min for 1 hr at 4 oC and the pH of the supernatant was measured. The supernatant was removed and the carboxylated CNTs were resuspended in Milli-Q water (Milli-Q Integral Water Purification System, Millipore Sigma) and then centrifuged. The pH of the supernatant was again measured and then removed. This process was repeated until the supernatant reached neutral pH. Samples were then dried at 60oC and stored at -20 oC until further use.  For deposition, 1.5 mg of functionalized CNTs were resuspended in 1.5 mL of Millipore-filtered deionized water by sonication for 5 
min. 1.5 μL of EDOT was pipetted in and the solution was vortexed for 2 min. The entire suspension was then sonicated using a probe sonicator (2 s on, 1 s off pulses for a total of 45 min).  Electrochemical deposition was done by chronocoulometry. 0.9 V was applied vs. Ag/AgCl reference (and Pt counter) and a charge cutoff was set to achieve a specific charge density on the surface. For example, for 15 mC/cm2 for a 7 μm i.d. x 400 μm length, the total charge cutoff should be set to 1.33 x 10-5 C.  
Electrochemical impedance spectroscopy. Cyclic voltammograms (Figure 36, 10 mM of hexaammineruthenium (III) chloride (Ruhex) dissolved in 100 mM KCl (both from Sigma Aldrich)) were taken before and after each coating. Sweep rate was 100 mV/s. Potential was scanned from -0.3 V to +0.7 and back to -0.3 V. Electrochemical impedance spectra 
(EIS) were also taken to verify the decrease in impedance due to the PEDOT/CNT coating. The three-electrode cell was connected to the Gamry Interface 1000E Potentiostat (Gamry Instruments).   A small (10 mV) RMS sine wave was applied vs. the open circuit potential and impedance was measured in the frequency range from 1-100kHz. An equivalent circuit model was fitted to the resulting spectra using Gamry Echem Analyst software v7.05. The circuits were created in the software and the different parameters were extracted using the 
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Simplex method. From these fits, the solution resistance can be extracted, converted to conductance (reciprocal), and then plotted as a function of solution conductivity to generate a calibration curve, in which the slope is equal to the inverse of the cell constant. 
In vitro particle experiments. The three-electrode system was set in place in a small vessel for in vitro experiments. 15 μm borosilicate beads (15.9 ± 0.6 μm diameter, 9000 Series Glass Particle Standards, ThermoFisher Scientific) were suspended in different concentrations of KCl and pipetted into the electrochemical cell. The particles were allowed to settle before any measurements are made. Impedance measurements were made in the particle bed first and then raised such that the entire electrode is in the conducting medium without particles and another measurement is taken. This way, there are two measurements per concentration of KCl, one with particles and one without. By plotting conductance vs. conductivity, two slopes were obtained: one with particles and one without particles. The ratio of the former slope to the latter yields the formation factor.  
Animals and surgery. All procedures involving animals were approved by the University of Pittsburgh Institutional Animal Care and Use Committee (Protocol #14125186). Male Sprague Dawley rats (250-275 g, Charles River) were anesthesized with isofluorane (5% by volume O2 initially and then 2.5% by volume for maintenance) and wrapped in a homeothermic blanket (Harvard Apparatus), which is set to 37 oC. After anesthesia, the rats were placed in a stereotaxic frame (Harvard Apparatus). Isofluorane was administered throughout the experiment. Holes were drilled into the skull in the appropriate positions (Bregma -0.8 mm AP, +/- 1.50 mm ML, and 0.8-4.0 mm below the surface of the brain). A hole was drilled for the reference electrode, which was put into contact with the brain using a salt bridge. The dura was removed with a scalpel for all electrode implantation.   
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Finite element calculations. A cylindrical model was created in COMSOL Multiphysics to represent the carbon fiber microelectrodes. A significantly larger (1 mm i.d. x 1 mm long) cylinder enclosed the microelectrode to represent the bulk electrolyte solution. Ground was chosen to be one of the enclosing walls of the larger cylinder. All other boundaries are insulation. A 10 mV AC potential was applied at the top surface of the 400-μm long electrode. The corners were rounded to prevent any sharp corner anomalies. The electric field in the model geometry was solved in the frequency domain from 1-100 kHz, with five points per decade. 
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4.3 RESULTS AND DISCUSSION 
4.3.1 Characterization of carbon fiber microelectrodes coated with PEDOT/CNT 
 
 
Scanning electron microscopy was used to image the surface of the carbon fiber microelectrodes 
before and after coating (Figure 36A and C). Bare carbon fiber microelectrode has a striated 
surface due to the presence of numerous nanofibers. After coating, however, the surface is 
Figure 36. A) Scanning electron microscopy image of bare microelectrode. B) Comparing and contrasting the 
cyclic voltammograms of a bare vs. a coated electrode. Im is the current and Vf is the potential. There is an 
oxidation of hexaammineruthenium (III) chloride (Ruhex) at -80 mV and a reduction peak at -250 mV. 
The non-Faradaic current magnitude is higher for coated than bare as indicated by inset, meaning 
that there is higher double layer capacitance for the coated than bare electrode.  C) SEM image of a 
coated microelectrode with PEDOT/CNT. D) Bode modulus plot comparing and contrasting bare and coated 
electrodes. Zreal is the real component of the impedance and Zimag is the imaginary component of the 
impedance. There is a nice charge-transfer limited semi-circle in the coated Nyquist plot. SEM images 
courtesy of I. Mitch Taylor of Prof. Tracy Cui’s group in the Department of Engineering at the University of 
Pittsburgh. All coated data are for 15 mC/cm2 surface charge density. 
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covered in a “bird-nest” like texture, with a significant increase in effective surface area. Cyclic 
voltammetry reveals that if electrodes are not soaked in isopropyl alcohol for 10 min before any 
measurements, there is no oxidation or reduction peaks for Ruhex. After soaking, however, the 
bare electrode has an oxidation peak at -80 mV and a reduction peak at -250 mV against 
Ag/AgCl reference electrode. The peak amplitude does not change after coating with 
PEDOT/CNT for a total charge density of 15 mC/cm2 (Figure 36B). However, the magnitude of 
the background non-Faradaic current in the plateau region (~200 mV) is increased by four-five-
fold (see inset in Figure 36B). We can calculate a double layer capacitance using the simple 
equation , where C is the magnitude of the capacitance, i+ is the magnitude of the 
current in the forward sweep towards positive potentials, i- is the magnitude of the current in the 
backward sweep toward negative potentials, and υ is the sweep rate in V/s. For bare electrodes, 
the maximum capacitance is usually 5-8 nF. For coated, the capacitance usually increases by 4-5 
fold to 20-40 nF. EIS spectra before and after coating (Figure 36D) show that the Nyguist plot 
for a bare electrode is diffusion-limited at all frequencies while that for a coated electrode has a 
nice charge-transfer limited semicircle section. In our experiments, this semicircle portion does 
not appear unless the capacitance of the double layer is ≥20 nF.  Overall impedance is also 
significantly reduced after coating. 
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4.3.2 Equivalent circuit modeling and depth test 
 
We developed an equivalent circuit model to extract the resistance of the surrounding medium 
around the microelectrode. Generally an electrode-electrolyte interface can be modeled with a 
Randles circuit, which consists of solution resistance (Rsolution) in series with both a double layer 
capacitance (Cdl) and charge transfer resistance (Rct), which are in parallel with each other 
(Figure 37). A constant phase element (CPE), an imperfect capacitor, is in series with the 
solution resistance and models the impedance due to diffusing redox species31 and can be 
 
Figure 37. A) Equivalent circuit modeling without shunt capacitor. B) Plot of conductivity as a function of 
conductance at two different depth in a beaker experiment at 20 oC. C) Equivalent circuit modeling with a 
shunt capacitor added. D) Plot of conductivity as a function of conductance at two different depths. The 
difference between depth 1 and depth 2 is approximately 2 cm. The error bars indicate error from the fitting. 
The regression analyses were done in Stata using analytic weights, which are inverses of the variances for 
each data point.  The conductance values are all on the order of 10-4 S (e.g. 2 x 10-4 S), but the 10-4 has been 
divided out for clarity. Inverse of the slope x 100 yields the cell constant in cm-1. 
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observed at low frequencies. While work characterizing the impedance properties of a single 
carbon microelectrode due to fouling has been done243, no measurement using carbon fiber 
microelectrode to measure solution resistance has been reported previously. In the first 
generation of the equivalent circuit model (Figure 37A), we observed that the calibration curve 
in different concentrations of KCl solutions is dependent on the depth of the electrode submerged 
in the solution (Figure 37B). In fact, the slopes are significantly different based on regression 
analyses at the 95% confidence level. At each concentration of KCl, there appears to be a higher 
conductance measurement at a greater depth. Robinson244 reported that there need to be a 
capacitor in parallel to the entire equivalent circuit to model all of the shunt capacitances (Cshunt) 
to ground from the tip to the input of the amplifier. This capacitor takes into account the 
capacitance that arises due to the separation of two conducting media (one inside the electrode 
comprised of Hg and one outside the electrode comprised of the salt solution) by the insulating 
glass as well as other stray capacitances from connectors and shielded wires244. This capacitance 
is particularly significant at the tip of the microelectrode where the glass insulation is thin, as 
capacitance is inversely related to the distance between two charging surfaces. Robinson 
reported that the magnitude of the shunt capacitance (in 10-100s of pF) is linearly dependent on 
the depth of immersion in the conducting medium. The slope of this plot gives the dielectric 
constants of the medium in which the electrode is submerged. We thus added a capacitor in 
parallel to the entire circuit to account for this shunt capacitance (Figure 37C). After this shunt 
was included, the calibration curve became independent of depth (Figure 37D), which is 
important for any implantation in vivo where measurements are taken at different depths. 
Interestingly, looking at the values of the different fitted parameters, depth did not impact Cdl, 
Rct, or CPE but did impact Rs and Cshunt. The value for Cdl and CPE were not affected by the 
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concentration of the KCl but all other values were dependent on the conductivity of the medium. 
The range of values for Cshunt was 10-50 pF, in agreement with those observed by Robinson244. 
We did observe that at low (<0.15 S/m) conductivity, there is deviation from linearity when 
plotting conductance vs. conductivity. It appears that below this level, the electrode becomes less 
sensitive to its conductivity and the slope changes. This is indication that the current is passing 
through a parallel path. We are currently unsure what the source of this parallel path is. We 
know, however, that the magnitude of the resistance of this path is approximately 20-50 kΩ and 
varies from electrode to electrode possibly due to variability in electrode fabrication. Raw data of 
the Nyquist plots for various concentrations of KCl can be found in the Supporting Information 
in Chapter 4.5.  
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4.3.3 Finite element simulation  
 
We created a simple 3D model in COMSOL Multiphysics (see Experimental section in Chapter 
4.2 and Supporting Information in Chapter 4.5) in which a cylinder is used to represent the 
microelectrode and a second, much larger cylinder (1 mm i.d. x 1 mm height) is used to represent 
the surrounding electrolyte medium. A potential of 10 mV was applied to the top surface of the 
microelectrode (see boundary 1 in Figure 43). The study was set up to solve in the frequency 
domain (1-100kHz). The resulting electric field profile is seen in Figure 38. Because of the 
incredibly small size of the working electrode relative to the reference and counter electrodes, 
 
Figure 38. Electric field profile in 100 mM KCl solution near the surface of the carbon fiber microelectrode 
at 20 oC. The maximum field is localized in the electrode front edges, which is not an artifact of sharp 
corners, as the corners are rounded in this geometry. The highest electric field strength is near the electrode 
surface (~2000 V/m) but the field drops to 10% that within a radial distance of 10 μm from the probe, 
indicated by the white contour line.  
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most of the potential drop occurs near the working electrode. The electric field potential drops to 
10% of its maximum magnitude (~2000 V/m) within 10 μm radially from the carbon fiber 
microelectrode. This is a rough estimate of the spatial resolution of the method.  
4.3.4 In vitro model  
 
Once the equivalent circuit model was optimized, we then proceeded to in vitro experiments. In 
these experiments, the three-electrode system is set up in a vessel (Figure 39, left) such that the 
reference electrode is in contact via a salt bridge and all of the electrodes are in place before a 
suspension of 15-μm borosilicate particles are added. These particles were chosen because their 
sizes are comparable to the average sizes of neurons in the brain (~10 μm). The particles are 
allowed to settle around the working electrode, separating from the KCl solution in which they 
are suspended, forming a randomly packed bed of particles. This was repeated for a total of four 
different concentrations of KCl (20-100 mM) and the impedance spectra are measured from 1-
 
Figure 39. (Left) Photo of the in vitro experiment. CFME = carbon fiber microelectrode. (Right) Plot of 
conductance as a function of concentration of KCl with and without (wo) particles at 20 oC. In this in vitro 
brain surrogate, the particles are 15 μm borosilicate glass beads that randomly packed in solution. 
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100kHz. Fitting the equivalent circuit model with a shunt capacitor seen in Figure 37C to these 
spectra yields resistances that can be converted to conductances (Figure 39, right). First of all, 
there is a linear dependence of the conductance on the conductivity of the solution, with and 
without particles. Moreover, the conductance decreased at every concentration of KCl in the 
presence of the particles. This is in agreement with expectations that if the formation factor 
decreased due to the presence of particles (more tortuous and/or smaller porosity), it would 
decrease the conductivity of the solution. The average formation factor calculated for this bed of 
randomly packed borosilicate particles is 0.62 ± 0.07 (std. dev., n = 4 electrodes). This formation 
factor seems higher than what we expect for bed of randomly packed particles. However, this 
observation may be explained by the wall effect seen in packed beds for separation. The average 
porosity in cylindrical capillaries is dependent on the ratio of the column diameter (dc) to particle 
diameter (dp). When the dc/dp = 5, the porosity was observed to be 0.47, which is significantly 
higher than if the dc/dp ratio > 35 (porosity = 0.36-0.37)245. This phenomenon occurs because of 
the inability of particles to form a dense packing against the hard surface of the column wall245. 
Even though we are not packing a column of particles, the particles in the in vitro experiments 
are allowed to settle around the working electrode, which acts as a “wall” and thus the same 
effect should apply. Furthermore, these porosity values are for packed beds with optimized 
slurry, high pressure, and ultrasonication. In our system, none of these conditions apply and dc ≈ 
dp, thus the porosity should be even higher than 0.47, which is exactly what we observe. This is 
evidence that our method is sensitive to the changes in formation factor due to the presence of 
particles, which is a promising result for measuring formation factor changes in the brain. 
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4.3.5 In vivo experiments 
 
Next, we performed in vivo experiments in anesthesized male Sprague Dawley rat. The purpose 
of these experiments is to measure the changes in formation factor as a result of changes in the 
local region, e.g. from the cortex, corpus callosum, and into the ventricle, where the formation 
factor should be close to one since it is filled with cerebrospinal fluid. Temperature should not 
have any effects on the cell constant and thus calibration can be done at room temperature for 
measurements at body temperature. Figure 40 summarizes the results. The formation factor in 
the cortex regions (depth 0.8-2.4 mm) is 0.21 ± 0.02 (SEM). The corpus callosum formation 
factor is 0.40 ± 0.04 in the x-direction (because of the orientation of the electrode). The 
formation factor in the ventricle is 0.72 ± 0.06 (~3.2 mm depth). Even though our radial spatial 
resolution is ~10 μm (see Figure 38), the overall spatial resolution is limited by the length of the 
microelectrode. Thus, we hypothesize that the reason the formation factor in the ventricle is not 
equal to one is because 1) there is variability in sizes and shapes of the ventricle between 
individual rats and 2) the entire electrode may not be submerged in the ventricle (the electrode 
may be partially in contact with the surrounding tissue). In future work, the length of the 
 
Figure 40. A) Diagram showing the different regions of the brain as well as the placement of the electrode (tip 
length shown in red is drawn to scale, the shaft and diameters are not). B) Bright field image of fixed brain 
slice showing the probe track that was formed when the barrel of the electrode was lowered deep into the 
brain to leave a mark. C) Plot of formation factor as a function of depth. Depth 3.2 mm should be in the 
ventricles, which is filled with cerebrospinal fluid. C = cortex, CC = corpus callosum, V = ventricle.  
 111 
electrode can be optimized for better spatial resolution. However, it is possible that in order to 
maintain the same double layer capacitance, a thicker coating is required for a shorter electrode. 
4.4 CONCLUSION  
We developed a simple, rapid, robust method of determining formation factor of the porous 
medium, such as the brain, by adapting carbon fiber microelectrodes coated with PEDOT/CNT 
for electrochemical impedance spectroscopy. The method has a 10 μm radial resolution based on 
finite element results. This method is sensitive to the changes in formation factor in the absence 
and presence of 15-μm borosilicate particles and is also sensitive to in vivo regional changes. The 
diameter of the electrode, which is significantly smaller than the spacing between blood vessels, 
and the presence of the PEDOT/CNT coating should allow for chronic implantation of the 
microelectrodes in vivo with minimal perturbation to the tissue. Collectively, these promising 
results allow for future work in measuring changes in ECS structure due to microdialysis probe 
implantation and other related applications. 
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4.5 SUPPORTING INFORMATION FOR EIS MEASUREMENTS 
 
 
Figure 41. Example spectra for electrochemical impedance measurements for different concentrations of KCl 
at T = 20 oC. As seen, the x-intercept of the Nyquist plot is sensitive to the conductivity of the solution, 
ranging from 10-100 mM KCl in this case. X-axis is the real component of the impedance and the Y-axis is 






Figure 42. Example spectra in vivo T = 37 oC. The different colors represent different depth in the rat brain. 
X-axis is the real component of the impedance and the Y-axis is the negative of the imaginary component of 
the impedance. 
 
Figure 43. Mesh elements for finite element model. The corner is rounded and finely meshed. 
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Table 16. Boundary condition for Electric Currents module in COMSOL Multiphysics v5.3. J is the current 
density, σ is the conductivity, V is the voltage drop, Je is the external current density source, n is the normal 
vector, and I0 is the applied current. 
 
Boundary/Domain Boundary condition Equation, if applicable 
A-B Current conservation  0)( =−∇⋅−∇=⋅∇ eJVJ

σ  
All boundaries except 1 Electric insulation 0=⋅ Jn

  
1 Terminal, potential V = V0, where  
V0 = 10 mV 
Outer wall of domain B (not 
shown in Figure 43) 
Ground V = 0 
 
Table 17. Material properties for carbon fiber and electrolyte solution. 
 
Domain Property Value 
A Electrical conductivity 8.9 x 106 S/m 
Relative permittivity 3 
B Electrical conductivity 1.1615 S/m  
(for [KCl] = 100 mM at 20 oC) 





5.0  CONCLUDING REMARKS 
We have adapted the method of electroosmotic push-pull perfusion coupled to offline capillary 
liquid chromatography for quantitative measurement of ectopeptidase activity in live, intact 
tissue. We developed a robust finite element model for understanding the sampling conditions, 
including electric field, flow rate, Péclet number, spatial resolution, and collection efficiency, to 
name a few, without the need to perform expensive or otherwise impossible experiments in the 
laboratory. We also used the model as a guide for data analyses such that important parameters 
such as Vmax and Km in the extracellular space can be obtained from the sampling data.  
Electroosmotic push-pull perfusion coupled to offline capillary liquid chromatography 
fills a need for answering longstanding neuroscience questions that requires spatially-resolved 
quantitative measurements of membrane-bound enzyme activity in their native environment. One 
of the longstanding questions in neuroscience has been why the CA1 subregion of the 
hippocampus is more vulnerable to ischemic damage than its CA3 counterpart. Using our 
quantitative approach, we measured three-fold higher aminopeptidase activity in the CA1 than 
the CA3 region of the hippocampus. We hypothesized that this aminopeptidase activity may 
contribute to higher vulnerability of CA1 region to ischemic damage. Thus, using an ex vivo 
model of stroke in the form of OGD and propidium iodide fluorescence staining, we found that 
inhibition of the aminopeptidase activity in the CA1 using bestatin selectively reduced the 
damage seen as a result of ischemic conditions. Moreover, this neuroprotection was not observed 
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in the CA3 and this neuroprotection was reversed upon the addition of the delta-opioid receptor 
antagonist naltrindole hydrochloride. These results confirm our hypotheses that 1) the higher 
aminopeptidase activity in the CA1 region does contribute to selective vulnerability of this 
region to ischemic damage and 2) this contribution acts through an enkephalin- and delta-opioid 
receptor-dependent pathway. 
 It is important to note that our measurement of higher aminopeptidase Vmax in the CA1 
does not distinguish between the concentration and isoforms of the enzymes. Thus, interesting 
future work could use Western blotting to assess the amount of aminopeptidases (especially 
aminopeptidase N) present in the two different regions. Mass spectrometry analyses can also be 
used to assess the presence of different isozymes if present. There is literature evidence on 
different isozymes of aminopeptidase N being present in the gut, but it is unclear if these 
isozymes are also present in the central nervous system. Moreover, our measurements of enzyme 
activity were done pre-OGD and in other words, under basal conditions. It is unclear if OGD 
itself would differentially change the expression of the aminopeptidases in the two subregions of 
the hippocampus. The lack of this information does not change the conclusions in this work but 
would be interesting follow-up questions for the future. Lastly, despite the extensive studies of 
delta opioid receptor expression and endogenous enkephalins, it is unclear why we observe the 
interesting time-dependent effects for 20-, 30-, and 40-min OGD. More extensive studies are 
required to further understand this incredibly intricate and complex peptidergic system.  
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